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“The important thing is not to stop 
questioning. Curiosity has its own reason 
for existence. One cannot help but be in 
awe when he contemplates the mysteries 
of eternity, of life, of the marvelous 
structure of reality. It is enough if one 
tries merely to comprehend a little of this 
mystery each day.” 
 
Albert Einstein 
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Summary 
 
Antimicrobial resistance has spread dramatically in last 60 years leading to an 
increase in the number of deaths due to infection diseases. The excessive and often 
inappropriate use of antimicrobial drugs has led to the development of a new group 
of microorganisms, the Multidrug Resistant (MDR) bacteria, which show resistance 
toward the most common antibiotics. This phenomenon is becoming a serious threat 
to the public health and the economy. The bioprospecting of marine and extreme 
environments has yielded a noteworthy number of novel molecules with 
biotechnological applications from a wide range of macro and microorganisms, 
representing a very promising strategy to counteract MDR bacteria. The main gap is 
to have access to the real microbial biodiversity because less than 1% of 
microorganisms is cultivable in the laboratory conditions.  
In this project, new antimicrobial compounds have been discovered from bacteria 
and fungi by different strategies. In the first work, following a bioprospecting pipeline, 
Antarctic shallow water sediments were used to isolate microorganisms that were 
screened for their capability to inhibit the growth of selected MDR bacteria. A 
bioassay-guided purification approach allowed the identification of rhamnolipids (a 
class of glycolipids well known as biosurfactants) produced by a Pseudomonas 
gessardii strain able to strongly inhibit MDR strains, in particular Gram-positive 
bacteria. These molecules have many biotechnological applications, especially in 
bioremediation field and, over last years, as antimicrobial compounds.  The second 
work focuses the attention on the improvement of cultivation methods, exploiting a 
new device, the Miniaturized Culture Chip (MCC), for the isolation of “not-common” 
or novel bacteria. The innovation of this system is the possibility to grow 
microorganisms directly in their natural habitat simulating environmental conditions. 
By using the MCC an unexplored Antarctic strain, Aequorivita sp., was isolated. A 
genome mining approach on Aequorivita sp. was applied identifying the main 
biosynthetic gene clusters. The evaluation of its bioactive potential led to the 
discovery of three new intracellular aminolipids showing antimicrobial activity against 
methicillin resistant Staphylococcus aureus (MRSA) and anthelmintic activity against 
the nematode Caenorhabditis elegans. This was the first report that demonstrated 
the bioactivity of this strain and stimulates the research of new cultivation method by 
which obtain new and unexplored sources of compounds. The third work instead, 
gave more attention to marine fungi, well-known producers of secondary metabolites. 
Extracts of nine fungi isolated from the green alga Flabellia petiolata, collected from 
the Mediterranean Sea, resulted to be active against some pathogen bacteria. In 
particular, the chemical profiling of three marine fungi, Beauveria bassiana (MUT 
4865), Knufia petricola (MUT 4979) and a new fungal species (MUT 4861) expressed 
a high compounds variability, novelty and activity.  
The successful results of this project that combines the bioprospecting of hostile 
environments with the optimisation of the critical step of the “biodiscovery pipeline” 
confirmed the huge potential of microorganisms as producers of novel bioactive 
compounds and demonstrated that this research field is far from to be fully exploited. 
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Riassunto 
 
Il principale obiettivo di questa ricerca è la scoperta di nuovi composti bioattivi da 
macro e microrganismi marini. In particolare, considerando la preoccupante 
diffusione di batteri “Multidrug Resistant” (MDR), cioè resistenti alla maggior parte 
degli antibiotici presenti attualmente sul mercato, negli ultimi anni è nata l’esigenza di 
scoprire nuovi composti ad attività antimicrobica. Il problema ha proporzioni mondiali 
aumentando il numero di decessi ed i costi per la sanità pubblica; esso non è limitato 
ai soli batteri patogeni, ma anche a funghi, virus e parassiti. Recenti studi hanno 
evidenziato il potenziale di batteri e funghi isolati da ambienti estremi e da fonti 
marine come risorsa di nuovi composti bioattivi. Le motivazioni di questa scelta 
risiedono nell’evidenza che questi microrganismi devono affrontare condizioni molto 
dure per la sopravvivenza (alte pressioni, scarsità di nutrienti e di luce, temperature 
estreme) e l’elevata pressione selettiva può aver portato alla sintesi di diversi 
composti con potenziale antimicrobico e di notevole interesse biotecnologico e 
farmaceutico. Uno dei maggiori problemi che si riscontra nella lotta ai batteri multi-
resistenti è la difficoltà di scoprire antibiotici che non siano già stati studiati. In 
particolare, l’uso di tecniche di isolamento tradizionali porta all’identificazione di 
microrganismi comuni, i quali, con alta probabilità, produrranno molecole note. Una 
possibile soluzione potrebbe essere l’isolamento di microrganismi nuovi e quindi 
poco studiati per la produzione di composti antimicrobici. Il principale “gap” però è 
rappresentato dalla “non-coltivabilità” in vitro della maggior parte delle specie 
microbiche esistenti che, quando estrapolati dal proprio ambiente naturale, non 
riescono a crescere nelle condizioni riprodotte in laboratorio. Sono quindi necessari 
diversi approcci per l’isolamento di nuovi microrganismi come fonte di nuove 
molecole bioattive. L’accesso alla vera biodiversità microbica potrebbe aprire la 
strada a nuove importanti scoperte in campo scientifico. 
 
L’obiettivo di questo progetto di ricerca è stato l’isolamento di nuove molecole ad 
azione antimicrobica impiegando diverse strategie. Nella prima è stato sviluppato e 
ottimizzato un processo (Drug-discovery pipeline) che comprende la raccolta dei 
campioni ambientali da ambienti estremi, l’isolamento dei microrganismi, lo screening 
per la bioattività, l’estrazione, la purificazione e l’identificazione di molecole ad attività 
antibiotica ed interessanti dal punto di vista biotecnologico. Oltre alla ricerca in 
ambienti estremi, applicando nuove metodologie di isolamento e screening dei 
microrganismi, è stato possibile selezionare batteri poco studiati per la produzione di 
composti bioattivi (antimicrobici e antiparassitari). Oggetto della ricerca sono stati 
anche i funghi marini notoriamente noti come produttori di metaboliti secondari di 
interesse industriale. 
 
Capitolo 1. Batteri da ambienti estremi: una risorsa di molecole 
antimicrobiche  
 
Nel primo capitolo, sono stati utilizzati sedimenti marini antartici per l'isolamento di 
microrganismi. Per esplorare la biodiversità presente nei campioni, i sedimenti 
raccolti sono stati diluiti in quattro terreni di coltura differenti, sia in liquido sia in 
solido, e incubati per un tempo massimo di 45 giorni. Dopo il periodo di incubazione 
le colonie sono state raccolte usando stuzzicadenti sterili, aggiunte singolarmente in 
una piastra multi-pozzetto e incubate a 20 ° C per 10 giorni in agitazione (220 rpm). 
Tutte le colonie isolate sono poi state conservate a -80 °C con l’aggiunta di glicerolo. 
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Con l’obiettivo di selezionare microrganismi produttori di composti antimicrobici è 
stato eseguito uno screening primario mediante esperimenti di cross-streaking. 
Questo metodo permette di valutare l’attività antimicrobica di un ceppo batterico 
definito “tester” (nuovi isolati) contro un panel di batteri “target” (batteri resistenti agli 
antibiotici). Il ceppo “tester” viene strisciato su una metà di una piastra Petri 
contenete un terreno di coltura solido e incubato per 5 giorni ad una determinata 
temperatura. Durante il periodo di incubazione il batterio raggiungerà una fase 
stazionaria in cui produrrà e diffonderà all’interno del terreno di coltura le sue 
molecole, tra cui i metaboliti secondari. Al termine del periodo di incubazione i batteri 
“target” vengono strisciati perpendicolarmente sull’altra metà della piastra e incubati 
per 2 giorni a 37 °C (temperatura ottimale per i ceppi “target”). Alla fine verrà valutato 
il livello di crescita dei batteri “target”. La mancata crescita di uno o più batteri 
indicherà che il ceppo “tester” ha prodotto molecole in grado di inibirne la crescita. In 
questo lavoro il cross-streaking è stato ottimizzato per lo screening di batteri marini i 
quali non sono in grado di crescere sullo stesso mezzo di coltura dei batteri “target”. 
Per far fronte quindi a questo limite è stata messa a punto un’unica piastra Petri 
contenente due terreni di coltura differenti, uno adatto per la crescita di batteri marini 
e l’altro adatto per i batteri patogeni. Una volta selezionati potenziali produttori di 
molecole bioattive, questi batteri sono stati cresciuti in liquido variando il mezzo di 
coltura e altre condizioni di crescita per stimolare la produzione di composti 
antimicrobici. I mezzi di coltura esausti sono stati poi estratti con solventi organici al 
fine di creare una libreria di estratti da analizzare attraverso appositi saggi contro i 
target stabiliti. L’attività antimicrobica è stata valutata mediante saggi di inibizione in 
liquido contro batteri multiresistenti calcolando la minima concentrazione inibente 
(MIC). Gli estratti positivi per l’attività antimicrobica sono stati poi prodotti in larga 
scala per effettuare una purificazione. Al fine di ottenere composti puri e identificare 
le molecole biologicamente attive, gli estratti sono stati frazionati applicando una 
procedura di estrazione in fase solida (SPE), le frazioni sono poi state saggiate per la 
loro attività e quelle attive ulteriormente purificate tramite HPLC (cromatografia 
liquida ad alta prestazione). L’ultimo step ha riguardato la determinazione della 
struttura dei composti tramite l’utilizzo di NMR (Risonanza Magnetica Nucleare) e 
spettrometria di massa. Inoltre una nuova tecnica di co-coltivazione di microrganismi 
è stata utilizzata al fine di indurre l’espressione di geni silenti riportando promettenti 
risultati. 
 
Risultati conseguiti 
Circa 200 batteri antartici sono stati isolati e conservati in glicerolo alla temperatura 
di -80 °C. Una parte di questi batteri è stata sottoposta ad uno screening preliminare 
mediante il metodo del “Cross-streaking”. Questo metodo qualitativo permette di 
osservare interazioni antagoniste tra un ceppo “tester” e diversi ceppi “target”. 
Mediante questo metodo due batteri identificati come Pseudomonas gessardii C5 e 
Pseudomonas fluorescens T28 hanno mostrato un’attività antimicrobica contro alcuni 
patogeni target. Il ceppo P. gessardii C5 è stato selezionato per successivi studi in 
liquido. In particolare, questo batterio è stato inoculato in terreno liquido e dopo 5 
giorni di incubazione il materiale extracellulare è stato estratto mediante etile acetato, 
evaporato utilizzando un rotavapor e l’estratto così generato è stato impiegato per 
saggi di inibizione in liquido contro un panel di patogeni più ampio. Per questi saggi, i 
batteri patogeni sono stati incubati in piastre multiwell da 96 pozzetti in presenza dei 
vari estratti a diverse concentrazioni e la loro crescita è stata valutata misurando 
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l’assorbanza a 600 nm dopo 24 ore di incubazione a 37°C. L’estratto prodotto da P. 
gessardii C5 ha mostrato una potente attività antimicrobica contro diversi batteri 
target, in particolare l’attività più elevata è stata rilevata contro batteri Gram-positivi. 
Questo estratto è stato poi sottoposto ad una procedura di purificazione guidata dalla 
bioattività, mediante un frazionamento preliminare utilizzando colonne C18 SPE 
reverse phase che ha permesso di individuare la frazione attiva, la quale è stata 
ulteriormente purificata mediante HPLC. Analisi chimiche di NMR e spettrometria di 
massa hanno permesso di identificare le molecole attive. Si tratta di ramnolipidi, 
glicolipidi molto noti come biosurfattanti, ma con una potente attività antimicrobica. I 
ramnolipidi trovano applicazione in diversi settori industriali. Vengono utilizzati per il 
biorisanamento, nei detergenti e negli ultimi anni la loro attività antimicrobica, 
specialmente contro batteri Gram-positivi ha attirato l’attenzione delle aziende 
farmaceutiche. Al fine di incrementare la produzione di ramnolipidi o di indurre 
l’espressione di altri metaboliti, un particolare sistema di co-coltivazione è stato 
applicato. Quattro batteri diversi, ma isolati dallo stesso ambiente sono stati coltivati 
in colture miste e gli estratti ricavati sono stati valutati per la loro capacità di inibire la 
crescita di batteri resistenti agli antibiotici. Uno dei batteri selezionati ha mostrato una 
spiccata attività antimicrobica quando cresciuto in presenza di altri batteri rispetto alla 
coltura pura. Inducendo cambiamenti nell’espressione genica, questa tecnica 
potrebbe permettere l’isolamento di nuove sostanze da parte di batteri e funghi.  
 
Capitolo 2. Isolamento mediante “Miniaturized Culture 
Chip” di un batterio Antartico Aequorivita sp. come fonte di 
nuovi composti bioattivi 
 
Nel secondo capitolo è stato impiegato un nuovo approccio per l’isolamento di 
microrganismi mediante l’utilizzo del Miniaturized culture Chip (MCC). Il numero di 
specie batteriche esistenti va da 107 a 109, ma la maggior parte non è mai stata 
osservata o coltivata. La metagenomica ha dimostrato l'enorme ricchezza della 
biodiversità nel mondo microbico. La "sfida dei microrganismi incoltivabili" è un 
argomento che coinvolge gli scienziati da molti anni. Le ragioni dell'incoltivabilità 
sono diverse e molte ancora sono sconosciute. È evidente che alcuni batteri 
richiedono requisiti specifici per la crescita, presenti solo nel loro habitat, come la 
presenza di alcune comunità microbiche o la necessità di specifiche caratteristiche 
fisiche o chimiche dell'ambiente naturale (luce, ossigeno, pH, pressione, temperatura 
ecc.). Tra le strategie per la coltivazione di microrganismi nuovi o rari, la simulazione 
in vitro dell'ambiente naturale è sicuramente una delle più promettenti. L’innovazione 
portata dal MCC è proprio la possibilità di crescere i microrganismi direttamente nel 
proprio habitat naturale. L’MCC è un sottile chip di alluminio formato da migliaia di 
micro-pozzetti che possono alloggiare microrganismi diversi. Utilizzando una comune 
piastra Petri il chip viene posto direttamente sui sedimenti raccolti dall’ambiente, poi 
una soluzione degli stessi sedimenti viene diluita sulla superficie del chip e il tutto è 
incubato per permettere la crescita dei microrganismi, i quali per poter crescere 
dovranno necessariamente sfruttare i nutrienti provenienti dai sedimenti naturali e 
avranno la possibilità di comunicare con i microorganismi presenti all’interno dei 
sedimenti stessi su cui il chip è adagiato. L'uso di dispositivi innovativi in grado di 
riprodurre condizioni naturali aumenta la possibilità di coltivare diverse specie 
microbiche le quali possono essere impiegati nel settore farmaceutico e 
biotecnologico. 
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Risultati conseguiti 
 
Mediante l’utilizzo del MCC è stato possibile isolare 19 microrganismi da sedimenti 
Antartici. Le colonie, ben visibili mediante un microscopio a bassa risoluzione, sono 
state raccolte e utilizzate per analisi filogenetiche e microbiologiche. Diverse specie 
di batteri sono state isolate, evidenziando quanto sia fondamentale l’utilizzo di 
sedimenti/campioni naturali all’interno dei terreni di coltura formulati per l’isolamento. 
Tra tutti i batteri identificati l’attenzione è stata focalizzata sull’isolato Aequorivita sp. 
Oltre ad articoli riguardo la tassonomia di questo genere non sono presenti in 
letteratura altre informazioni, soprattutto riguardo la produzione di composti bioattivi 
da parte di questi batteri. Per prima cosa, in collaborazione con l’istituto Pasteur di 
Parigi il ceppo in esame è stato depositato nella loro collezione e ne è stato 
sequenziato il genoma completo. Quindi su Aequorivita sp. e altri batteri appartenenti 
al genere Aequorivita, depositati all’istituto Pasteur, è stata applicato un approccio di 
“Genome mining” identificando tutti i principali cluster biosintetici (indipendentemente 
dalla loro effettiva espressione) presenti nel genoma di questi batteri. 
Successivamente è stata valutata la capacità di inibire batteri resistenti agli antibiotici 
mediante saggi di inibizione in liquido e Caenorhabditis elegans come modello per 
trovare composti antiparassitari. I risultati hanno mostrato una promettente attività 
antimicrobica, soprattutto verso S. aureus meticillina resistente (MRSA) e 
antiparassitaria dell’estratto intracellulare (ottenuto distruggendo meccanicamente le 
cellule ed estraendo mediante acetato di etile) e la totale assenza di attività da parte 
dell’estratto extracellulare (ottenuto estraendo direttamente il brodo esausto 
mediante acetato di etile). Lo “scale-up” della coltura ha permesso di ottenere 
materiale sufficiente per la procedura di purificazione. L’uso di NMR e spettrometria 
di massa ha permesso l’identificazione dei composti attivi. In particolare sono stati 
identificati 8 amminolipidi di cui 5 noti e 3 non riportati in letteratura. Negli ultimi anni 
l’interesse per questa classe di molecole ad azione antimicrobica ha riscontrato un 
notevole incremento perché meno suscettibili all’insorgenza di resistenza da parte di 
batteri patogeni.  L’approccio utilizzato in questo lavoro, combinando la ricerca in 
ambienti estremi con nuovi metodi per l’isolamento di nuove specie batteriche ha 
permesso l’identificazione di nuovi prodotti di possibile interesse industriale e 
farmaceutico e l’esplorazione di ulteriori approcci che uniranno tecniche omiche e 
microbiologiche potrebbero migliorare i metodi di coltivazione attuali risultando nella 
scoperta di nuove molecole bioattive. 
 
Capitolo 3. Analisi del potenziale antimicrobico di funghi marini 
isolati da alghe per contrastare i batteri multi-resistenti: diversità 
filogenetica e caratterizzazione chimica. 
 
Nel terzo capitolo è riportata l’analisi del potenziale antimicrobico di alcuni funghi 
marini. Questi ultimi rappresentano un’importante fonte di metaboliti secondari. Si 
stima che il potenziale bioattivo di questi organismi sia notevolmente sottovalutato in 
quanto molto spesso i geni codificanti per composti bioattivi sono silenti e quindi non 
espressi in determinate condizioni. I funghi in esame sono stati isolati dall’alga verde 
Flabellia petiolata raccolta nel Mar Mediterraneo. Diversi terreni di coltura sono stati 
utilizzati per la crescita dei funghi in modo da selezionare le migliori condizioni di 
crescita ed eventualmente, di produzione. Acetato di etile ed acetone sono stati 
impiegati per effettuare le estrazioni dei brodi esausti e dei miceli preceduti da un 
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trattamento con azoto liquido necessario per rompere la parete cellulare. Tutti gli 
estratti sono poi stati aggiunti alle piastre contenenti i batteri target calcolando la 
minima concentrazione inibente. Gli estratti positivi sono poi stati sottoposti ad 
un’analisi chimica che ha permesso l’identificazione di diverse molecole attive. 
 
Risultati conseguiti 
 
I funghi sono stati selezionati in base alla presenza di geni codificanti per polichetide 
sintasi (PKS) e peptidi non-ribosomiali sintasi (NRPS). I funghi isolati (classificati con 
il codice MUT, in quanto appartengono alla Mycoteca Universitatis Turinensis) sono 
stati identificati a livello molecolare e assegnati alle classi Dothideomycetes, 
Sordariomycetes e Eurotiomycetes. Al fine di selezionare i migliori mezzi di crescita 
per la produzione di composti antimicrobici, sono state eseguite estrazioni preliminari 
e saggi antimicrobici su colture fungine in piccola scala coltivate in diversi mezzi di 
crescita. Queste analisi hanno dimostrato che il MeCl (20 g di estratto di malto, 17 g 
di NaCl) era il mezzo migliore per l'espressione dei composti bioattivi e pertanto è 
stato scelto per i successivi esperimenti. Inoltre, sono stati confrontati i potenziali 
antimicrobici degli estratti extracellulari e intracellulari e i risultati hanno mostrato una 
maggiore resa e attività di quest'ultimi. Partendo da questi risultati, gli estratti sono 
stati usati per lo screening antimicrobico contro un gruppo di batteri patogeni umani. I 
più attivi e promettenti erano MUT 4861 appartenente alla famiglia Microascaceae, 
MUT 4865, identificato come Beauveria bassiana e MUT 4979 identificato come 
Knufia petricola. In particolare, gli estratti in acetato di etile prodotti da MUT 4861 e 
MUT 4865 sono stati in grado di inibire l'intero gruppo di patogeni, con una 
percentuale di inibizione superiore al 50%. Inoltre, MUT 4861 è stato in grado di 
inibire fortemente B. metallica e P. aeruginosa con inibizione del 92% e 86% 
rispettivamente, mentre MUT 4865 ha mostrato una forte attività verso B. metallica 
(100%) e S. aureus (86%). L'estratto del MUT 4979 ha mostrato un'elevata attività (> 
80% di inibizione) contro 3 dei quattro patogeni, con l'unica eccezione di K. 
pneumoniae. Una completa analisi del profilo chimico degli estratti più promettenti ha 
permesso l’identificazione di nuove molecole bioattive ad azione antimicrobica. MUT 
4865 è una specie ben nota per la produzione di metaboliti secondari e nonostante 
ne siano stati isolati molti composti bioattivi, continua ad essere una notevole fonte di 
nuove molecole dimostrando una notevole variabilità genetica. Per quanto riguarda 
MUT 4861 e 4979 questo è il primo lavoro che ne evidenzia il ruolo di produttori di 
molecole antimicrobiche. 
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1. The antibiotic resistance crisis 
“It is not difficult to make microbes resistant to penicillin in the laboratory by exposing 
them to concentrations not sufficient to kill them, and the same thing has occasionally 
happened in the body...and by exposing his microbes to non-lethal quantities of the 
drug make them resistant”. Already in 1945, during his Nobel Prize lecture, 
Alexander Fleming pronounced these words and warned of the danger of resistance. 
Since this wise “prediction” the worldwide population successfully faced infectious 
diseases discovering many new antibiotics with a different mode of actions. Until the 
sixties, the world was in what is called “Golden Age” of antibiotic discovery. 
Moreover, by using chemical synthesis the number of new molecules exponentially 
increased, modifying and optimising natural products [1]. Antibiotics have 
successfully contributing to improve clinical surgery preventing or treating infections 
that can occur in patients who are receiving chemotherapy treatments; who is 
affected by chronic diseases such as diabetes, end-stage renal disease, or 
rheumatoid arthritis; or who have had complex surgeries such as organ transplants, 
joint replacements, or cardiac surgery [2-4]. For more than 20 years’ human being 
hold and used these powerful molecules to defeat bacteria, but then, between the 
1960s and 2000, no new major classes of antibiotics were discovered (Fig. 1) and 
furthermore, pharmaceutical companies reduced microbial screening programs (one 
of the best source of bioactive compounds) due to their declining productivity and 
challenging regulatory barriers [5, 6]. The development of new antimicrobial agents 
had become a more complex, costly and lengthy process. On an average, research 
and development of anti-infective drugs take around 15-20 years and can cost more 
than 1 billion dollars [7]. The politics of the regulatory authorities, like the US Food 
and Drug Administration (FDA) have also contributed to the problem by failing to 
approve drugs endowed with non-inferior properties.  
 
 
Figure 1: The timeline shows the ‘Golden Age’ of antibiotic discovery (1940–1960) and the ‘Golden Age’ of 
antibiotic medicinal chemistry (from 1960 to present). No new structural classes of antibiotics were introduced 
between 1962 and 2000, representing a serious innovation gap during the genomic era. 
 
After this period defined “Innovation gap” few new drugs were developed, but 
microorganisms exploited their flexible metabolic power to adapt to existing drugs. It 
is not surprising that many bacteria became resistant to antibiotics because in billion 
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years of evolution they developed different strategies for survival, but what is 
alarming is their capability to acquire resistance in a very short time. Resistance to 
antibiotics was reported a few years later their approval as showed in Table 1. For 
example, Linezolid approved in 1999 and used for the treatment of infections caused 
by Gram-positive bacteria registered a Staphylococcus aureus resistant strain in the 
same year [8]. The same happened with Fidaxomicin the first in a new class of 
narrow spectrum macrocyclic antibiotic drugs approved in 2011 and active especially 
against clostridia [9].  
 
Antibiotic Year deployed Clinical resistance observed Ref. 
Sulfonamides 1930s 1940s [10] 
Penicillin 1943 1946 [10] 
Streptomycin 1943 1959 [10] 
Chloramphenicol 1947 1959 [10] 
Tetracycline 1948 1953 [10] 
Erythromycin 1952 1988 [10] 
Vancomycin 1956 1988 [10] 
Methicillin 1960 1961 [10] 
Ampicillin 1961 1973 [10] 
Cephalosporins 1960s Late 1960s [10] 
Nalidixic acid 1962 1962 [11] 
Fluoroquinolones 1980s 1980s [12] 
Linezolid 1999 1999 [8] 
Daptomycin 2003 2003 [13] 
Retapamulin 2007 2007 [14] 
Fidaxomicin 2011 2011 [9] 
Bedaquiline 2013 2013 [15] 
Ceftazidime/avibactam 2015 2015 [16] 
Table 1: Evolution of resistance to clinical antibiotics 
 
One of the explanations for this phenomenon is the uncontrolled use of antimicrobial 
agents and the adaptation strategies of microbes. The overuse of antibiotics and 
many times the incorrect prescription of them contribute to the developing of 
resistance [17, 18]. A huge amount of antibiotics (80% in the U.S. according to 
estimations) is used in livestock to promote growth and to prevent infections and this 
significantly contributes the developing of some resistances [6, 19]. Moreover, in the 
bacterial world, the horizontal gene transfer allows the exchange of genetic material 
(plasmids carrying genes for antibiotics resistance) intra and inter-species conferring 
resistance to many classes of antibiotics [18]. In addition to acquired resistance, 
microorganisms can be intrinsically resistant to different molecules [20].  
The selective pressure caused by the use of antibiotics led to the development of a 
new class of bacteria, Multidrug Resistant (MDR) bacteria. Most of them are resistant 
to at least three classes of antibiotics and represent a serious threat to public health 
[21]. Today, more than 70% of pathogenic bacteria are resistant to most antibiotics 
on the market, and the frequency of multi-drug resistance in the community have 
extended the resistance problem beyond the confines of the hospital [22]. 
Reappearing “old pathogens” and new re-emerging opportunistic pathogens could 
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potentially recreate the pre-antibiotic era. So diseases and disease agents that were 
once thought to be controlled by antibiotics are returning in new leagues resistant to 
these therapies [22, 23]. Recently, February 2017, World Health Organization (WHO) 
published a list of antibiotic-resistant "priority pathogens" – a catalogue of 12 families 
of bacteria that pose the greatest threat to human health 
(http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-
needed/en/). The list was drawn up in a bid to guide and promote research and 
development (R&D) of new antibiotics, as part of WHO’s efforts to address growing 
global resistance to antimicrobial medicines. Some of the most problematic MDR 
organisms include genera like Acinetobacter, Pseudomonas, Enterobacter, 
Staphylococcus and others. These MDR bacteria can cause severe and often deadly 
infections and they are very often found in hospitals [24]. The issue of MDR bacteria 
has global dimensions, but poor life condition of developing and underdeveloped 
countries aggravates this problem. Resistance to common drugs is not limited to 
bacteria but also to fungi, viruses and especially parasites. Among parasites, a 
prominent role is played by nematodes. Gastrointestinal nematodes, such as the 
blood-sucking Haemonchus contortus, are major parasites of ruminants that cause 
substantial economic losses to livestock production worldwide. Inevitably, drug 
resistance has emerged in human and livestock pathogenic helminths against each 
class of antihelmintic compounds [25].  
The “never-ending story” between antibiotics and resistant organisms cannot be 
stopped, but understanding the mechanisms of resistance and focusing the attention 
on unexplored areas, we can increase the possibilities to discover new effective 
drugs. 
 
1.1 Mechanisms of antibiotic resistance  
Bacteria were one of the first life forms appearing on Earth, about 3.8 billion years 
ago and if they survived until now, it is due to their ability to adapt to the external 
world, fighting for food and evolving strategies to resist to antimicrobial agents 
produced by competitors. Recently, many bacteria become resistant to most of the 
antibiotics released on the market employing several mechanisms in attaining 
multidrug resistance. Resistance obviously has a genetic basis: it can be intrinsic, via 
mutation of an endogenous chromosomal gene, or acquired by incorporation of the 
foreign genetic material into their chromosome by conjugation, transduction, and 
transformation [26, 27]. A brief description of main mechanisms for antibiotic 
resistance in bacteria are summarised below [28] and showed in Figure 2; 
Impermeability: antibiotics with intracellular target have to penetrate outer and/or 
cytoplasmic membrane in order to exert their function. Bacteria can decrease the 
uptake of antimicrobial compounds by membrane molecules, such as 
lipopolysaccharide (LPS) [29]. Especially in Gram-negative bacteria, changes in 
surface hydrophobicity, outer membrane ultrastructure, outer membrane protein 
composition, and change in outer membrane fatty acid composition, all changes that 
decrease the permeability of membrane barriers. 
Efflux systems pump: drug efflux systems pump out a broad range of chemically 
and structurally unrelated compounds from bacteria in an energy-dependent manner, 
without drug alteration or degradation. This mechanism was first described for 
tetracycline in the late 1970s [30]. 
Target alteration: through this mechanism antibiotic are not able to bind the target. 
In some cases, the binding site is protected by other molecules, like in the case of 
tetracycline resistance [31]. Other mechanisms include the modification of target site 
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by point mutations, enzymatic alterations of the binding site (e.g. addition of methyl 
groups), and/or replacement or bypass of the original target. 
Antibiotic modification or destruction: bacteria evolved the capability to produce 
enzymes able to inactivate or degrade the antibiotic itself. One of the best examples 
of resistance via modification of the drug is the presence of aminoglycoside 
remodelling enzymes (AMEs) that covalently modify the hydroxyl or amino groups of 
the aminoglycoside molecule, while enzymes like β-lactamases destroy the amide 
bond of the β-lactam ring, rendering the antimicrobial ineffective [32].  
Resistance due to global cell adaptations: complex mechanisms are used by 
bacteria to regulate cell wall synthesis and membrane homeostasis. Although the 
exact mechanism mediating this phenomenon has not been fully elucidated, it 
appears to involve alterations in cell wall metabolism that results in changes in 
surface charge producing electrostatic repulsion and avoiding the interaction with 
particular charged antibiotic molecules such as Daptomycin [33]. 
 
 
Figure 2: Principal mechanisms of antibiotic resistance 
 
Despite the presence of some mechanisms of resistance, molecules targeting 
bacterial membrane still seems to be the best choice to face the antibiotic resistance. 
One emerging class of compounds, called AMLPs (antimicrobial lipopeptides), shows 
promise features that make these molecules good candidates for drug development. 
In particular, they are less vulnerable to evolved resistance because they disrupt the 
structure and function of microbial membranes. Microbes, to evolve drug resistance, 
would require many big changes to alter the mixture of lipids composing the 
membrane. AMLPs are small and stable lipophilic molecules and could represent a 
promising alternative to traditional antibiotics. Past studies have shown that these 
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synthetic compounds have potent activity against a range of pathogens and can clear 
infections in mice [34].  
 
2. Bioprospecting of natural products from marine and extreme 
environments 
The concomitant relentless increase in antibiotic resistance infections, coupled with 
the failure to find new antibiotics, signals a return to the pre-antibiotic era. To 
counteract this phenomenon, different strategies are needed. The bioprospecting of 
unexplored environments like extreme and marine habitat could lead to the discovery 
of new Natural Products (NP). NP represent the largest source of new antibiotic 
molecules, covering about two-thirds of new antibacterial therapies approved 
between 1980 and 2010 [35, 36]. Thinking about extreme habitat, Antarctica is one of 
the most extreme places on Earth. Although most of the continent is covered by 
glacial ice sheets, ice-free areas comprising approximately 0.4% of the continental 
land mass are discontinuously distributed around the coastal margins. Some areas 
are polar deserts characterized by extremely low annual precipitation (<100 mm) and 
an absence of vascular plants and vertebrates; most of the biological activity is 
limited to the top four or five inches by the permanently frozen ground below. Mean 
summer high and low winter temperatures in the dry valleys are −5 °C and −30 °C 
[37, 38]. There is a high level of UV exposure and long periods of light/dark. The 
isolated and unique nature of Antarctica attracted the attention of scientists. The 
reasons are obvious; in comparison to many over-explored tropical areas, Antarctica 
and the ocean that surrounds it is home to a large number of unknown organisms 
adapted to the “extreme cold and conditions”. These “extremophiles” exhibit physical 
and chemical adaptations not found elsewhere on the planet [39]. As a fact, some 
Antarctic places are studied for the exploration of Extra-terrestrial life because of its 
peculiar environment [40]. In some way, marine environments could be considered 
as an extreme habitat. They include a wide range of temperature, salinity, light and 
pressure encountered by life. Within the oceans, habitats can range from tropical 
sunlight surface waters to ocean trenches with 110 MPa pressure at 11 km below 
sea level. Furthermore, temperatures in the ocean can be over 350 ºC in pressurised 
fluids in hydrothermal vents and as low as -35 ºC in channels within the sea ice. If we 
consider the vastness of the aquatic environment, it is possible to appreciate the 
great importance of focusing scientific efforts on marine bioprospecting to look for 
new molecules. Although the diversity of life in the terrestrial environment is 
extraordinary, marine environment is estimated to be the richest source of 
biodiversity in the world [41]. In recent years, bioprospecting applied to marine and 
extreme environments have led to the development of a wide variety of natural 
compounds, especially secondary metabolites with unique biological activities [42] 
and high potential for biotechnological and pharmaceutical applications. Furthermore, 
areas beyond the limits of national jurisdiction, such as open seas and Antarctica, are 
still not strictly regulated by Nagoya Protocol (which aims at sharing the benefits 
arising from the utilization of genetic resources in a fair and equitable way) [43] and it 
makes less complicated the access to the biological resources. From 2001 to 2016, a 
vast amount of new biological natural compounds with various activities, such as 
antibacterial, antitumor, antiviral and so on, have been isolated from polar and 
marine organisms including microorganisms, lichen, moss, bryozoans, cnidarians, 
echinoderms, molluscs, sponges and tunicates [44]. Several compounds showing the 
same bioactivity were discovered in different places in the marine environment [45-
47]. For example, anthracimycin, a new antibiotic produced by a marine-derived 
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actinomycete has been discovered [48]. This molecule shows significant activity 
against Bacillus anthracis and several Gram-negative bacteria. Another antimicrobial 
compound named Exophilin A, which inhibits the growth of Gram-positive bacteria 
has been found from a marine fungus [49]. One of the best sources of NP remain 
microorganisms, including bacteria and fungi and going to unexplored areas could 
increase the chances to discover different species able to produce novel bioactive 
compounds.  
 
2.1 Antarctic bacteria 
Bacteria able to grow at low temperatures are classified as psychrophiles, which can 
grow at temperatures not exceeding approx. 15 °C and psychrotrophs (or 
psychrotolerants) that tolerate a broader range of temperatures, between 15 °C and 
30°C [50]. Microorganisms evolved different mechanisms which permit they to 
tolerate extremely low temperatures. These mechanisms include the increasing of 
membranes fluidity, the ability to accumulate compatible solutes (e.g. glycine, betaine 
and trehalose), the expression of cold shock, antifreeze and ice-nucleating proteins, 
as well as the production of cold-active enzymes [50-52]. Studies have shown that 
Antarctic bacteria are an incredibly rich source of unique enzymes, proteins and 
other bioactive compounds that can benefit industry [53]. More attention has been 
focused on cold-adapted enzymes, but recently several new NPs showing 
antimicrobial activity have been isolated from Antarctic bacteria. An intracellular 
biomolecule similar to anthraquinone and indane derivatives of a diterpenoid isolated 
from an Antarctic cyanobacterium showed antibacterial activity towards Gram-
positive Mycobacterium tuberculosis, S. aureus, Gram-negative Salmonella typhi, 
Pseudomonas aeruginosa and three MDR strains of Escherichia coli [54]. Two 
pigments named violacein and flexirubin were isolated from two Antarctic bacterial 
strains. The two compounds displayed antibacterial activities against some 
mycobacteria with low MIC values (ranging from 2.6 to 34.4 µg/mL) and might be 
valuable natural lead compounds for new antimycobacterial drugs used for 
tuberculosis chemotherapy [55]. Two new rhamnolipids showing inhibition effects 
against Burkholderia spp. and S. aureus were isolated from an Antarctic 
Pseudomonas sp. [56]. 
 
2.2 Marine fungi 
From the discovery of the antibiotic cephalosporines in 1948 [57], marine fungi have 
been considered an excellent source of bioactive compounds and since the 1980s, 
the number of new antimicrobial compounds discovered from marine fungi is 
increased. They represent a huge reservoir of biologically active secondary 
metabolites that are often produced by multifunctional enzyme complexes such as 
PolyKetide Synthases (PKSs) and Non-Ribosomal Peptide Synthetases (NRPSs). 
Metabolomic and genomic studies on marine fungi have shown the presence of 
many unexpressed biosynthesis genes which could encode for unknown metabolites 
[58]. Several studies by Kong et al. demonstrated the tremendous potential of marine 
fungi as producers of unknown molecules with novel scaffolds [59], which might be 
useful for drug discovery [60] but in contrast to bacteria, the basic knowledge of 
marine fungi, such as distribution and ecological role is still scarce. These promising 
data encourage the scientific efforts towards the exploitation of the marine fungi and 
considering that a large part of the marine ecosystem is still unexplored, we can 
speculate that a huge number of new molecules is waiting to be discovered. Marine 
fungi have been retrieved from various marine habitats from superficial waters 
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mangroves, marine algae, and salt marshes (mostly in association with marine 
invertebrates) until the deep subseafloor. True marine fungi can grow and sporulate 
exclusively in seawater, where facultative marine fungi are able to adapt away from 
their natural habitat [61]. The physical factors that influence the marine fungi are a) 
salinity and pH, b) low water potential, c) high concentration of sodium ions, d) low 
temperature, e) oligotrophic nutrient conditions and f) high hydrostatic pressure, the 
last three parameters being unique to the deep-sea environment [61]. In response to 
their environment, marine fungi can produce a wide range of secondary metabolites. 
Many reports describe the great antibacterial and antifungal activity of extracts 
produced by marine fungi [62-64], most which isolated from a marine host exploiting 
their capability to maintain mutualistic relationships with algae or sponges. An isolate 
of a Pestiolata sp. from the brown alga Rosenvingea sp., collected in the Bahamas 
islands, produced the chlorinated benzophenone pestalone, a compound that 
showed an inhibition effect against methicillin-resistant S. aureus and Enterococcus 
faecium [65]. This compound was then produced by chemical synthesis (not 
confirming the same level of bioactivity) [66]. Natural compounds sometimes contain 
minor impurities which are the real responsible for their bioactivity). From the fungal 
broth of a marine Aspergillus species isolated from the surface of the marine brown 
alga Sargassum horneri in Korea yielded a new polyoxygenated decalin derivative, 
dehydroxychlorofusarielin B, which was found to exhibit antibacterial activity against 
MDR S. aureus [67]. Although linking biological activities to any ecological role 
remains a difficult task, the amazing range of bioactivities of marine fungi suggests 
that these secondary metabolites could be defensive compounds and therefore is 
likely to play important roles in symbiosis and competition with other organisms in 
their habitats. Most metabolites reported from marine environment are produced by 
Aspergillus and Penicillium [68] meaning that they express many genes responsible 
for the production of antimicrobial compounds, but several times the exploitation of 
these strains lead to the discovery of well-known metabolites.  
 
3. Microbial “uncultivability” 
Although the bioprospecting of unexplored environments is a promising strategy to 
isolate microbial species able to produce unknown bioactive compounds, that is not 
enough. Most of the time, as a fact, the application of classic isolation techniques 
leads to the identification of very common microbial species, which produce known 
molecules. The result is a huge waste of time and money. The point is, that is very 
difficult to isolate rare or novel strains since they are not cultivable in laboratory 
conditions. The problem of microbial “uncultivability” is an issue that involves 
microbiologists for many years. Molecular-based approaches demonstrated that 
approximately less than 1 % of microorganisms present in an environmental sample 
is cultivable in vitro [69, 70] and it drastically limits scientists' knowledge of microbial 
life and their derived products. There are several explanations for this phenomenon. 
Certain bacteria have fastidious growth requirements including the need for specific 
nutrients, pH conditions, incubation temperatures or levels of oxygen in the 
atmosphere [71]. Another important factor is the extrapolation of microorganisms 
from the natural environment, which naturally contains specific nutrients, signal 
molecules produced by indigenous microbial communities that contribute to building 
a network of signals essential for the growth of many bacteria [72, 73]. Bacterial 
communication is an essential factor to retrieve unknown species. Many terms are 
used to describe microbes that are not able to grow under laboratory conditions, but 
the “not-yet-cultivated” microorganisms seem the correct definition. They play 
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important ecological roles in their habitat and sometimes are the most abundant and 
ubiquitous species [74], but still, lab conditions are not suitable for their growth; so 
they are just “not-yet-cultivated”. Significant efforts have been made in recent years 
developing new strategies for the isolation of new strains. The majority of culture 
media used to date have been nutrient-rich. This condition may favour the growth of 
fast-growing bacteria at the expense of slow-growing species, some of which are 
oligotrophic and may be inhibited by substrate-rich conventional media. 
Consequently, the use of dilute nutrient media and the extension of incubation time 
has led to the successful cultivation of previously unculturable bacteria from various 
aquatic and terrestrial habitats [75]. Other strategies include the use of helper strains 
as a source of growth factors and the simulation of natural environment using 
innovative devices diffusion chambers and isolation chips [76, 77]. The access to real 
microbial biodiversity could lead to a new era of biodiscovery with many novel 
antibiotics discovered and exploited against the emergence of MDR bacteria. The 
first step in this direction was the isolation by the iChip, a new system composed of 
microwells and semipermeable membranes, of a new β-proteobacteria provisionally 
named Eleftheria terrae able to produce a new antibiotic, the Teixobactin [78]. This 
study highlighted the importance of new organisms such as uncultured bacteria as a 
source of new antimicrobials. 
 
4. The unexpressed potential of the genome 
Recent advances in DNA sequencing technologies allow the whole genome 
sequencing in a rapid and cost-effective way. As a consequence, new tools for the 
genome analysis were developed (BAGEL for the identification of bacteriocins [79], 
and AntiSMASH for the identification of a wide range of biosynthetic clusters) ranging 
from PKS and NRPS to siderophores [80]. Genome mining approach (a rapid 
approach to discover new and novel secondary metabolites for drug discovery using 
genome data) has revealed that microorganisms contain genes to produce other 
natural products, but often they are silent or cryptic biosynthetic gene clusters [81, 
82]. It means that they are not expressed under certain conditions. The concept of 
“laboratory conditions” again play a fundamental role in the discovery of new natural 
products. Applying the right stimuli/strategies/approaches to microbes, the 
overexpression of some genes or the induction of silent genes will be possible. 
Various strategies changing the growth conditions can be applied to induce 
secondary metabolites production. The OSMAC approach (One Strain Many 
Compounds) and co-cultivation with other organisms gave the best results regarding 
new bioactive compounds [83, 84]. These different approaches, mainly the co-
cultivation, are based on the assumption that, in the laboratory, many 
microorganisms (bacteria and fungi) are not stimulated enough in comparison with 
their natural environment where they live in communities and have to fight for the 
survival. Limitations of these techniques are represented by the selection of the right 
conditions, but the recent advancements in the HPLC-MS/MS allow the rapid 
comparison of metabolites profiling and a guided selection of the best condition. The 
aim is to detect any variation in the microbial metabolism in response to different 
stress. Finally, thanks to the information obtained by genome mining and 
metabolomics data the NPs discovery process can be accelerated. 
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5. Marine Biotechnology  
Marine (or blue) biotechnology encompasses the sustainable use of marine 
resources for biotechnological applications addressing global challenges of food, 
energy, and health. Over the last years, the impact of the marine biotechnology on 
the bioeconomy is considerably increased. The global market for marine 
biotechnology products and processes is predicted to reach US$4.8 billion by 2020, 
rising to US$6.4 billion by 2025 [85]. In Europe, marine biotechnology was identified 
by the EU Blue Growth Strategy (2012) as an enabling activity of high potential for 
the bioeconomy. Through EU funding, new consortia and marine infrastructure are 
born creating new jobs and bringing innovations. It is considered an area of great 
interest and potential due to the contribution for the building of an eco-sustainable 
and highly efficient society. Marine biotechnology has a horizontal scope 
encompassing very different applications. It includes techniques such as 
bioprocessing, bioharvesting, bioprospecting, bioremediation leading to the discovery 
and exploitation of new natural products of industrial interest. In particular, drug 
discovery represents one of the most promising research field [86]. The history of 
marine drug discovery is rich of molecules that entered in clinical and pre-clinical 
studies [87] highlighting the importance of investing in this field. An example of 
successful “blue business” that provides ‘proof-of-concept’ for exploiting marine 
chemical diversity in human health is demonstrated by the marine‐derived natural 
product Trabectedin (ET‐743; Yondelis®), a potent antitumor originally isolated from 
the Caribbean Sea squirt, Ecteinascidia turbinata and currently prepared synthetically 
[88]. The relevance and impact of the marine biotechnology on the society and 
bioeconomy is clear encouraging the development of new processes and 
technologies aimed to the discovery of new products. 
 
6. Aim of the project 
The aim of this project was the exploitation of microorganisms as a source of novel 
bioactive compounds able to counteract the spread of MDR bacteria which represent 
a serious threat to the public health. The project is divided into three chapters which 
explore different strategies for the identification of novel antimicrobial compounds:  
Chapter 1: In this chapter, a “Drug-discovery pipeline” was applied. Classic isolation 
techniques were used to isolate bacteria from Antarctic sediments. Then a procedure 
of bioassay-guided purification was used in order to evaluate the antimicrobial 
potential of the most promising bacteria against a panel of MDR bacteria. Moreover, 
several strains were selected for co-cultivation experiments with final aim to induce 
the expression of “silent” bioactive compounds. 
Chapter 2: In order to discover rare or new microorganisms, an innovative device 
which allowed to mimic the natural environment was used. By this method an 
unexplored Antarctic bacterium was isolated, the whole genome was sequenced and 
new antimicrobial compounds were identified from this strain.  
Chapter 3: In this chapter, the screening of novel marine fungi, isolated from the 
green alga Flabellia petiolata collected from the Mediterranean Sea, showed the 
presence of fungal strains endowed with strong inhibitory activity against MDR 
bacteria. The chemical profiling of the most active strains led to the identification of 
the bioactive molecules. 
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Bacteria from the extreme:  
a source of antimicrobial compounds 
 
Abstract 
 
Recently, the uncontrolled use of antibiotics led to the widespread of multidrug 
resistant (MDR) bacteria becoming a serious threat to human health. The Golden 
Age of antibiotics comes to an end. There is the pressing need to discover novel 
effective antimicrobial compounds and the bioprospecting of extreme environments 
could be a promising strategy. In this work, Antarctic shallow water sediments were 
used to isolate microorganisms that were screened for their capability to inhibit the 
growth of selected MDR bacteria. Among the isolates, one belonging to 
Pseudomonas genus showed a high antimicrobial activity against the pathogens 
panel, especially against Gram-positive bacteria. The purification of molecules 
responsible for the bioactivity and the structure elucidation by NMR and LC-MS-MS 
allowed the identification of a family of rhamnolipids, an important class of bioactive 
compounds with many biological functions of biotechnological and pharmaceutical 
interest. 
 
1.1 Introduction 
 
Antimicrobial resistance has spread dramatically in last 60 years leading to an 
increase in the number of deaths due to infectious diseases. The excessive and often 
inappropriate use of antimicrobial drugs has led to the development of a new group 
of microorganisms, the MDR bacteria, which show resistance toward the most 
common antibiotics. This phenomenon is becoming a serious threat to public health 
and the economy [1]. In contrast, the development of new antimicrobial agents has 
slowed down due to lack of interest in the pharmaceutical industry. Indeed, in the last 
two decades, only two antibacterial drugs with a new mode of action have been 
progressed into the market [2]. New strategies are needed to address this problem 
and slow down the spread of drug resistance. For example, in 2012 FDA has 
implemented the Generating Antibiotics Incentives Now (GAIN) Act, a provision 
within the Food and Drug Administration Safety and Innovation Act (FDASIA), to 
promote the development of new antibacterial and antifungal drugs. The US 
government has issued “The National Strategy for Combating Antibiotic Resistant 
Bacteria”, which identifies priorities and coordinates investments to prevent, detect, 
and control outbreaks of resistant pathogens. Nowadays, infections caused by 
antibiotic-resistant bacteria, such as the “ESKAPE” pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species), Burkholderia cepacia complex 
(Bcc) and others, are increasing human mortality [3]. Many of these bacteria are also 
able to produce biofilms that are relevant in a wide range of clinical domains 
including intensive care medicine, surgery [4] but also other sectors as the food 
industry [5]. In biofilms, bacteria are quite well protected against antibacterial 
treatments. Furthermore, biofilms can release harmful toxins and even obstruct 
indwelling catheters [6]. It is hence obvious that an effective screening program has 
become an urgent and unmet need for isolation and identification of new molecules. 
In that sense, bioprospecting of marine and extreme environment, like Antarctica, 
represents a very promising strategy for the isolation of microorganisms as a source 
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of new natural drug candidates. Those environments remain largely unexplored in 
comparison to terrestrial ecosystems and organisms. In order to survive in such 
environments, microorganisms have accumulated remarkable physiological and 
functional heterogeneity, and currently, constitute an unlimited reservoir of genetic 
diversity [7]. The easier access to those environments in recent years has led to the 
development of a wide variety of marine-derived compounds, especially secondary 
metabolites with unique biological activities [8] and high potential for biotechnological 
and pharmaceutical applications. Several antibacterial [9], antifungal [10] and 
antiviral [11] compounds have been isolated from marine organisms, so far. In this 
work, the identification of bioactive compounds of biotechnological and 
pharmaceutical interest was performed following a bioprospecting pipeline. 
  
1.2 Materials and Methods 
 
Isolation of bacterial strains 
In this work, Antarctic shallow water sediments were used for the isolation of 
microorganisms. To explore the biodiversity present in the samples, two strategies 
were applied. In the first strategy, 1 g of sediment was mixed with 9 mL of sterile 
water, homogenized using a vortex, serially diluted (10-1, 10-2 and 10-3) and each 
dilution was plated on four different solid growth media and incubated at 4 and 20 °C 
for 45 days. Incubation times were extended until 45 days to increase the 
microorganisms number and allow the development of slow-growing strains. For the 
second strategy, 1 g of the same sediment was added directly to four different liquid 
media and incubated with agitation at 150 rpm at the same temperature of solid 
plates. Periodically (after 1, 3, 5, 10, 20, and 45 days) 100 µL of liquid cultures were 
plated on the respective solid media. This procedure allowed observing the changing 
in the microbiome during the time. Growth media used for the experiments are listed 
below. 
 Marine Broth (MB): 19.4g NaCl, 8.8g MgCl, 5g Bacteriological Peptone, 3.24g 
NaSO4, 1.8g CaCl2, 1g Yeast Extract, 0.55g KCl, 0.16g NaHCO3, 0.10g 
Fe(III) Citrate, 0.08g KBr, 0.034g SrCl2, 0.022g H3BO3, 0.008g Na2HPO4, 
0.004g Na-Silicate, 0.0024g NaF, 0.0016g NH4NO3, pH 7.6 at 25°C.  
 Tryptic Soy Broth (TSB): 17g Pancreatic Digest of Casein, 3.0g Papaic Digest 
of Soybean, 5.0g NaCl, 2.5g K2HPO4, 2.5g Dextrose, pH 7.3 
 Glycerol Arginine (GA): 20g Glycerol, 2.5g L-Arginine, 1g NaCl, 0.1g CaCO3, 
0.1g MgSO4.7H2O, 0.1g FeSO4.7H2O (added as solution after sterilisation) 
 Starch Casein (SC): 10g Soluble Starch, 2g K2HPO4, 2g KNO3, 2g NaCl, 0.3g 
Casein, 0.05g MgSO4.7H2O, 0.02g CaCO3, 0.01g FeSO4.7H2O (added as 
solution after sterilisation) 
 Luria-Bertani broth (LB): 10 g/L Tryptone, 5 g/L Yeast extract, 10 g/L NaCl. 
This medium was used for the growth of the pathogen and the scale-up of the 
antimicrobial producing strain. 
The composition of selected media is expressed in grams per Litre of distilled water. 
Solid media were prepared adding 15 g/L of Agar.  50 mg/L of Nystatin was added to 
each medium to inhibit the growth of fungi. 
After the incubation period, colonies were picked using a sterile wooden toothpick 
added individually on a 96 multi-well plate and incubated at 20°C for 10 days under 
agitation (220 rpm). Each well contains 200 μL of liquid growth medium (the same 
medium used for the isolation). The isolated bacteria were then suspended in 
glycerol (20% final volume) and stored at -80°C. 
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MDR bacteria used as target 
The following strains of human pathogens were used in this work: Pseudomonas 
aeruginosa Pa01, Staphylococcus aureus 6538P, Klebsiella pneumonia DF12SA, 
Acinetobacter baumannii Ab13, Propionibacterium acnes DSM 1897, Enterococcus 
faecalis DSM 20478, Burkholderia anthina LMG 20980, Burkholderia diffusa LMG 
24065 and Burkholderia metallica LMG 24068. The strains were routinely grown at 
37°C in LB medium. 
 
Cross streaking 
Preliminary screening for antimicrobial activity was performed by the cross-streaking 
method. This method allows the observation of antagonistic interactions among a 
tester strain (newly isolated bacteria) and several target strains (MDR bacteria). 70 
µL of overnight bacterial cultures are spread on half plate and incubated for 5 days a 
20 °C. During this period, the secondary metabolites produced by the tester strain 
are able to diffuse into the agar. After 5 days’ target strains are streaked 
perpendicularly the tester strain and the plate is incubated at 20 °C for 1 day and 37 
°C for 2 days. To overcome the limitation of the assay that the pathogens and the 
tester strains are not able to grow on the same medium, a dual media Petri dish was 
developed. From one side of the plate, the culture medium was poured to allow the 
growth of Antarctic isolates and the other half of the plate was filled with LB medium, 
suitable for the growth of MDR bacteria. Then tester and target bacteria were added 
as described. A control, a plate inoculated with pathogens was also maintained 
without inoculating the new isolates to assess the normal growth of MDR bacteria. 
 
Molecular identification and phylogenetic analysis of isolated strains 
The freeze and thaw method was used to obtain bacterial genomic DNA, which was 
used as a template for the amplification via PCR of 16S rDNA genes. PCR was 
carried out in a total volume of 50 µL containing DreamTaq PCR Master Mix (a 
ready-to-use solution containing DreamTaq DNA Polymerase, optimized DreamTaq 
buffer, MgCl2, and dNTPs) and 1 µM of primer Eub27F (Forward, seq: 5'-
AGAGTTTGATCCTGGCTCAG-3') and Univ1492R (Reverse, seq: 5'-
GGTTACCTTGTTACGACTT-3') [12]. The reaction conditions used were: one cycle 
(93 °C for 2 min), 30 cycles (92 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min), with 
a final extension of 5 min at 72 °C. PCR products were then purified, sequenced and 
submitted to BLAST for the phylogenetic analysis. 
 
Extract preparation 
A single colony of a bacterial isolate was used to inoculate 3 mL of liquid SC and LB 
media in sterile bacteriological tubes. After 48 h of incubation at 20°C at 200 rpm, the 
pre-inoculum was used to inoculate 125 mL of the same media in 500 mL flasks, at 
an initial cell concentration of 0.01 OD600/mL. The flasks were incubated up to 5 days 
at 20°C at 200 rpm. The cultures were then centrifuged at 6800 x g at 4°C for 30’, 
and the exhausted culture broths were collected and stored at -20°C. The exhausted 
culture broths were subjected to organic extraction using 3 volume of ethyl acetate in 
a 500 mL separatory funnel. The organic phase collected was evaporated using a 
Laborota 4000 rotary evaporator and the extracts were weighted, dissolved in 100% 
DMSO at 50 or 100 mg/mL and stored at -20°C. The extract for the scale-up of the 
culture was obtained using the same protocol increasing the volume up to 3 L. 
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Liquid Inhibition assay 
The produced crude extracts were checked for the ability to inhibit the growth of a 
selected panel of human pathogens using the Minimal Inhibitory Concentration (MIC) 
assay. The following MDR bacteria were used for the antimicrobial screening: 
Burkholderia metallica LMG 24068, Pseudomonas aeruginosa PA01, Klebsiella 
pneumoniae DF12SA, Acinetobacter baumannii Ab13 and Staphylococcus aureus 
6538P. All the bacteria were routinely grown at 37°C in Luria-Bertani broth. The 
extracts were placed into each well of a 96-well microtiter plate at an initial 
concentration of 2 mg/mL and serially 2-fold diluted using the appropriate medium. 
Wells containing no compounds represent the negative control. DMSO (2% v/v) was 
also used as a control to determine the effect of the solvent on bacterial growth. For 
the plate inoculum, a single colony of each pathogen strain was used to inoculate 3 
mL of liquid medium in sterile bacteriological tubes. After 5-8 h of incubation, growth 
was measured by monitoring the absorbance at 600 nm and about 40000 CFU were 
dispensed into each well of the prepared plate. Plates were incubated at 37°C for 20 
hours and growth was measured by using a VICTOR X Multilabel Plate Reader 
(PerkinElmer, Waltham, MA) by monitoring the absorbance at 600 nm. 
 
Purification of ethyl-acetate crude extract 
The crude extract obtained from the scale-up was subjected to fractionation using 
Chromabond SPE C18 column cartridges (Macherey-Nagel, Duren, Germany) and 
selectively eluted with different percentages of a methanol-water system. Five 
fractions were obtained: 25%, 50%, 75%, 100%, and 100% methanol with 0,04% 
TFA. Each fraction was dried, weighted and assays were carried out to determine the 
most active fraction. The active fraction was further purified by reverse-phase HPLC 
on a C18 column. HPLC separations were carried out using a 5μm Nucleodur 
reversed-phase HTec (C18, 250/10 mm, L × i.d.) column connected to an UltiMate 
3000 series pump and monitored using an UltiMate photodiode array detector. 
Detection was carried out at 220, 254, 280 and 320nm. The gradient was ran using 
Buffer A (95% H2O, 5% Acetonitrile+0.04% TFA and Buffer B 5% H2O 95% 
Acetonitrile+0.04% TFA) at a flow rate of 3.00mL/min. Used gradient as described in 
Table 1.  
 
Time (min) Flow rate 
(mL/min)
% of mobile 
phase Aª 
% of mobile
 phase Bᵇ
Initial 3.0 100 0
7.00 3.0 80 20
28.00 3.0 60 40
35.00 3.0 40 60
42.00 3.0 0 100
56.00 3.0 0 100
ªMobile phase A: 95% Water - 5% Acetonitrile + TFA0.004%
ᵇMobile phase B: 95% Acetonitrile - 5% Water + TFA0.004%
 
Table 1: HPLC gradient used for the purification of antimicrobial compounds 
 
Identification of the antimicrobial compounds 
Isolated molecules were chemically characterized by a combination of by 1D and 2D 
omo- and heteronuclear NMR spectroscopy and by HRESIMS analysis in 
collaboration with the Department of Pharmacy of Federico II University in Naples.  
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Co-cultivation experiment 
For this experiments, two special 500mL bottles were used. Each bottle has a glass 
neck by which is possible to make a connection with the other one. The necks are 
separated by a 0.22 µm filter that allowed the only exchange of molecules (from the 
medium or produced by bacteria) avoiding the bacterial physical contact. The system 
is closed using an aluminium clamp. Each bottle was filled with 150 mL of liquid 
growth medium and inoculated with two different bacteria. The system was incubated 
at 20 °C at 150 rpm for 5 days. Finally, the intracellular and extracellular material of 
each condition was submitted to the same extraction and screening process 
explained above. 
 
1.3 Results 
 
Isolation of microorganisms 
Marine Antarctic sediments were used for the isolation of microorganisms using two 
approaches. Part of the sediment was serially diluted and plated on four different 
solid growth media MBA, SCA, GAA and TSA. In this way, the isolation of different 
classes of bacteria was carried out. The other approach consisted in the observation, 
in liquid conditions, of the microbiome variation during the time. For this purpose, 1 g 
of the same sediment was added directly to liquid cultures (kept in agitation) and 
periodically, 100 µL of cultures were plated on agar media as described in MM. The 
incubation time was extended to 45 days to allow the development of slow-growing 
strains using two temperatures, 4 and 15 °C. After 45 days, a morphological analysis 
was performed in order to collect the colonies. Plates at 4°C showed a less number 
of colonies and less biodiversity compared with plates at 15 °C. GAA resulted to be 
the worst medium in terms of variability and colonies number. Differences in the type, 
shape, number and colour were observed comparing the isolates obtained by the two 
approaches (solid and liquid). From liquid cultures a sort of microbial selection during 
the time was clear. Different microbial population appeared on plates at different 
times (Fig.1). A remarkable variation after 45 days in TSB liquid was observed. As a 
fact, only two different colonies, labelled T1 and T2, were able to grow on plates 
(very close to each other) from liquid TSB. In total, about 200 colonies were picked 
and stored in 96 well-plates at -80 °C.  
 
 
Figure 1: Differences in the microbial population isolated periodically from liquid Marine Broth. A= 3 
days, B= 5 days, C= 10 days, D= 20 days.  
 
Primary screening: optimisation of cross streaking assay 
In order to check the ability of Antarctic bacteria to inhibit the growth of a panel of 
MDR bacteria, composed by Burkholderia metallica LMG 24068, Pseudomonas 
aeruginosa PA01, Klebsiella pneumoniae DF12SA, Staphylococcus aureus 6538P, 
and Acinetobacter baumannii Ab13, cross-streaking experiments were performed. 
The limitation of this technique is that the tester bacteria (new isolates) and the target 
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strains (MDR bacteria) must grow on the same growth medium. The problem is that 
many marine and Antarctic bacteria are not able to grow on such media. In this work, 
we optimise the cross streaking assay building a dual-media on the same plate as 
described in MM. The selected bacteria were spread onto half petri dish containing 
the suitable media and incubated at 15°C for five days. This ensures any secondary 
metabolites produced were diffused into the agar. Among 74 bacteria tested 6 
showed an inhibition activity against some pathogens. Results are reported in Table 
1. In particular, the isolate labelled as C5 and initially isolated from liquid SC (after 3 
days of incubation) was able to completely inhibit the growth of S. aureus and B. 
metallica. 
 
Strain B3 C3 C5 T28 D10 
S. aureus +/- +/- - - + 
P. aeruginosa + + + + + 
K. pneumoniae + + +/- +/- +/- 
A. baumannii +/- +/- + +/- + 
B. metallica +/- + - +/- +/- 
Table 1: Growth of pathogen strains in the presence of Antarctic isolates in cross streaking 
experiment. Symbols: +, growth, +/- reduced growth, -, no growth. 
 
Phylogenetic affiliation of C5, T28, T1 and T2 strains 
The 16S rDNA genes of isolate C5 was amplified by PCR and the obtained sequence 
was submitted to BLAST for the strain identification. The antimicrobial producer strain 
C5 showed 99% of sequence similarity with Pseudomonas gessardii and T28 was 
identified as Pseudomonas fluorescens. Other two isolates T1 and T2 were 
submitted to the same procedures and respectively identified as Lysobacter sp. and 
Pseudoachromobacter sp. These two strains were isolated after 45 days of 
incubation growing very close to each other and could be used for co-cultivation 
experiments. 
 
Antimicrobial activity of Pseudomonas gessardii C5 
The most active strain Pseudomonas gessardi C5 was inoculated in liquid media LB 
(this medium was selected because is suitable for the growth of Pseudomonas 
strains) and after five days extracted by ethyl acetate. The produced crude extract 
was checked for the ability to inhibit the growth of a selected panel of human 
pathogens in a liquid inhibition assay, evaluating the minimal inhibitory concentration. 
After 24 h of incubation at 37°C the results confirmed the promising antimicrobial 
activity of P. gessardii C5 towards several pathogens, mainly Gram-positive bacteria 
(Table 2, values reported as percentage of growth inhibition). The highest 
antimicrobial activity was detected against E. faecalis with a MIC value of 15 μg/mL. 
Both S. aureus and MRSA were inhibited with a MIC value of 30 μg/mL. No 
significant effect was observed towards gram-negative strains except for the 
Burkholderia genus. This strain was selected for further studies. 
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Extract 
concentration 
1 
mg/mL 
0,5 
mg/mL 
0,25 
mg/mL 
0,13 
mg/mL 
0,06 
mg/mL 
0,03 
mg/mL 
0,015 
mg/mL 
0,007 
mg/mL 
0,003 
mg/mL 
DMSO 
+ cells 
Cells 
only 
S. aureus 91 91 90 91 87 83 52 0 0 0 0 
MRSA 89 90 90 90 83 82 5 2 0 0 0 
P. acnes 91 89 72 48 19 7 28 22 17 0 0 
E. faecalis 96 91 90 91 90 90 82 14 11 0 0 
P. aeruginosa 0 0 0 0 0 0 0 0 0 0 0 
K. pneumoniae 0 0 0 0 0 0 0 0 0 0 0 
A. baumannii 14 9 8 7 1 7 1 1 1 0 0 
B. metallica 89 89 89 54 0 0 0 0 0 0 0 
B. anthina 87 87 87 44 2 0 0 0 0 0 0 
B. diffusa 87 87 83 74 58 0 0 0 0 0 0 
Table 2: Antimicrobial activity of P. gessardii C5 crude extract against a panel of MDR bacteria. 
Bacterial growth is measured in OD600/mL. Red colour indicates the strong inhibition of the extract at a 
certain concentration while green colour indicates no inhibition.  
 
Bioassay-guided purification 
P. gessardii C5 was submitted to the scale-up of the culture in order to obtain a 
sufficient amount of crude extract for the purification. Subsequently, the crude extract 
(1,5 g) was fractionated and the 4 eluted fractions were collected, dried and 
dissolved in DMSO to perform bioassay at a stock concentration of 50 mg/mL for 
MIC assay, Table 3. The fraction eluted at 100% methanol (89 mg) was the most 
active one against S. aureus with a MIC of 15 μg/mL (From now on, S. aureus was 
used as reference Gram-positive strain for the evaluation of antimicrobial activity). 
 
Extract 
concentration 
1  
mg/mL 
0,5 
mg/mL 
0,25 
mg/mL 
0,13 
mg/mL 
0,06 
mg/mL 
0,03 
mg/mL 
0,015 
mg/mL 
0,007  
mg/mL 
0,003 
mg/mL 
DMSO 
+ cells 
Cells  
only 
Crude 
Extract 
90 90 89 89 87 84 35 7 11 0 0 
N.B. 0 0 0 0 0 0 0 0 0 0 0 
25% 0 0 0 0 0 0 0 0 0 0 0 
50% 0 0 0 0 0 0 0 0 0 0 0 
75% 86 49 0 0 0 0 0 0 0 0 0 
100% 90 90 90 90 90 90 90 78 30 0 0 
Table 3: Antimicrobial activity of P. gessardii C5 fractions against S. aureus. Bacterial growth is 
measured in OD600/mL. Red colour indicates the strong inhibition of the extract at a certain 
concentration while green colour indicates no inhibition. 
 
The active fraction was then submitted to HPLC separation. HPLC chromatograms 
extracted from 200 to 400 nm presented 10 different peaks, which were separated, 
dried and dissolved in DMSO at a stock concentration of 10 mg/mL to perform MIC 
assay. Data obtained revealed a high inhibitory activity against S. aureus of five 
compounds numbered C1-5. (Table 4). 
 
 MIC 
Strain C-1 C-2 C-3 C-4 C-5 
S. aureus 7 µg/mL 5 µg/mL 5 µg/mL 3 µg/mL 3 µg/mL 
Table 4: Minimal inhibitory concentration of pure compounds against S. aureus.  
 
 
Chemical analysis of active metabolites 
According to the NMR analysis, all the isolated compounds belong to the mono-
rhamno-di-lipid sub class (Fig. 2). This classification was easily inferred by the 
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presence in the 1H NMR spectrum of only one anomeric signal (H ca 4,80 bs) and 
one C5 methyl group (H 1.26,d 6,4, C 16.5), relative to the mono-rhamnpyranosyl 
unit and of two low field pentet signals at ca 5.27 ppm and 4.10 ppm relative to the 3-
hydroxymethine protons of the two fatty acid chains. Compounds 3 and 5 have never 
been isolated so far.  
 
 
Figure 2: Structures of the rhamnolipids isolated from Pseudomonas gessardii C5 
 
The analysis of the negative pseudo-molecular ion [M-H]-, obtained by ESI-HRMS 
gave information on the molecular formula, whereas the analysis of the key fragment 
ion arising from the cleavage of the ester linkage between the two -hydroxy fatty 
acid units allowed to discriminate between congeners with non-symmetric fatty acid 
units (Table 5). Fragmentation spectra are shown in section 1.6 Supplementary 
materials (Fig. S1-5). For instance, the molecular formula C24H44O9 for compound (1) 
corresponds to a structure Rha-C8-C10 or Rha-C10-C8. The key fragment at m/z 305, 
corresponding to Rha-C8 allowed to assign the structure Rha-C8-C10. Compound 2 
and 4 correspond respectively to Rha-C10-C10 and Rha-C12-C10. Negative ESI–HRMS 
gave the main pseudo-molecular ion at m/z 529.3373 for compound 3, indicating a 
molecular formula C28H50O9, consistent with Rha-C10-C12:1 or Rha-C12:1-C10. The 
main ion in the corresponding MS/MS spectrum at m/z 359, corresponding to the 
cleavage of the ester bond, allowed to assign the Rha-C12:1-C10 structure. The 
molecular formula of the compound 5 was established as C30H54O9 by HRESIMS 
analysis of the pseudo-molecular ion, which implied an additional C2H4 unit, 
compared to compound 3. MS/MS fragmentation data evidenced two daughter ions 
at m/z 387.29 and 223.21 corresponding to Rha-C14:1 and C14:1 (-H2O) negative ions, 
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that allowed to assign a C-14:1 fatty acid chain linked to rhamnose unit. The 13C and 
1H chemical shifts of compounds 3 and 5 are shown in Table S6 in Supplementary 
materials. The structure of the compound, including the position of the double bond in 
the fatty acid and the identity and configuration of the anomeric proton of the sugar 
moiety, was secured by detailed NMR analysis, based on HMQC, COSY, TOCSY 
and ROESY experiments. 
 
Rha-FA-FA Formula [M-H]- 
MS/MS 
fragments  
Relative 
abundance 
RhaC8C10 (1) C24H44O9 475.2916 305 1.9% 
RhaC10C10 (2) C26H48O9 503.3227 333 4.3% 
RhaC12:1C10 (3) C28H50O9 529.3373 359 49.3% 
RhaC12C10  (4) C28H52O9 531.3536 361 40.4% 
RhaC14:1C10 (5) C30H54O9 557.3376 
387,  223, 163, 
119, 103 
4.1% 
Table 5: Molecular formula, pseudomolecular-ions, ion fragments and relative abundance of isolated 
compounds derived from HRMS/MS.  
 
In addition, the fractionation of the crude extract also gave an enriched fraction, that 
contains as determined by LC-HRESIMS analysis, in positive mode, a mixture of 3-
(3-hydroxyalkanoyloxy) alkanoic acids that lack the carbohydrate moiety and 
represent precursors of rhamnolipids (Fig. 3). 
 
36 
 
 
Figure 3: LC-HRESIMS analysis, in positive mode of a fraction containing a mixture of 3-(3-
hydroxyalkanoyloxy) alkanoic acids that lack the carbohydrate moiety and represent precursors of 
rhamnolipids. 
 
Preliminary Co-cultivation experiments 
During this work, many bacterial strains were isolated. Some of them showed 
antimicrobial activity in the conditions that we selected, but there are other 
approaches that could be applied to induce the expression of bioactive compounds. 
One of the strategies is the so-called Co-cultivation. It is based on the idea that 
microbes in nature don’t live in axenic cultures but in communities, exchanging signal 
molecules, nutrients, etc. and for this experiment, we tried to simulate these 
conditions and to provoke variation in their metabolism. Special cultivation bottles 
were used for the experiment. This system is made up of two bottles connected with 
a glass neck and separated by 0.22 µm filter that allowed the only exchange of 
molecules (from the medium or produced by bacteria) avoiding the bacterial physical 
contact. Different co-cultivation experiments were tried involving: the rhamnolipids 
producer P. gessardii C5, the other strain, P. fluorescens T28 that showed weak 
inhibition activity during the cross-streaking experiments against almost all 
pathogens, then Lysobacter sp. T1 and Pseudoachromobacter sp. T2 initially isolated 
from TSB liquid cultures after 45 days. They were selected because of their capability 
to grow very close to each other on the agar plate, meaning that they communicated 
in some way. Co-cultivation experiments using P. gessardii C5 and P. fluorescens 
T28 together and with the other selected strains showed no significant variation 
regarding growth and bioactivity. Further studies will be performed co-cultivating P. 
gessardii C5 and S. aureus to increase rhamnolipids production exploiting the 
antagonistic effect. While the two Pseudomonas strains showed no variations in this 
system, the co-cultivation between Lysobacter T1 and Pseudoachromobacter sp. T2 
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displayed a positive result. Each bacterium was inoculated in one bottle and 
incubated for five days with agitation (Fig. 4A). Finally, each bottle, containing a 
specific strain was centrifuged and analysed separately. A different colour of the 
pellet of Lysobacter T1 strain grown in co-cultivation was immediately clear, 
compared with the control (Fig. 4B, 2C) 
  
 
Figure 4: Co-cultivation bottles inoculated with Lysobacter sp. T1 (left bottle) and 
Pseudoachromobacter sp. T2 (right bottle) joined by a glass neck separated by 0.22 µm filter and 
respective controls inoculated as pure cultures in single bottles (A). Bacterial pellet after centrifugation 
with a visible colour variation of T1 grown in co-cultivation with T2, compared with the pure culture (B, 
C).  
 
Pellet and supernatant of the two bacteria were extracted by ethyl acetate and the 
obtained extracts were evaluated for their capability to inhibit pathogen bacteria. 
Results showed an increased inhibitory effect (about 15 fold) towards S. aureus of 
the intracellular extract produced by Lysobacter sp. T1 co-cultivated compared with 
control, Fig. 5. The presence of Pseudoachromobacter sp. T2 in co-cultivation bottles 
induced some variation in the T1 metabolism resulting in an increased bioactivity. No 
significant antimicrobial effects were detected by Pseudoachromobacter sp. T2 and 
against other pathogen bacteria. 
 
Extract 
concentration 
1 
 mg/mL 
0,5 
mg/mL 
0,25 
mg/mL 
0,13 
mg/mL 
0,06 
mg/mL 
0,03 
mg/mL 
0,015 
mg/mL 
0,007 
mg/mL 
0,003 
mg/mL 
DMSO 
+ cells 
Cells  
only 
T1 Cntrl 83 84 52 40 16 6 5 4 0 0 0 
T2 Cntrl 35 18 16 16 11 7 7 7 0 0 0 
T1 CoCult 100 100 100 100 91 42 22 27 0 0 0 
T2 CoCult 49 19 11 9 7 6 23 34 0 0 0 
Figure 5: Antimicrobial activity of Lysobacter sp. T1 and Pseudoachromobacter sp. T2 crude extracts 
against S. aureus. Bacterial growth is measured in OD600/mL. Red colour indicates the strong 
inhibition of the extract at a certain concentration while green colour indicates no inhibition 
 
Finally, a chemical profiling by HPLC comparing the Lysobacter sp. T1 intracellular 
extracts was performed to appreciate variations in the bacterial metabolism caused 
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by the co-cultivation. Results reported in Figure 6 show a difference in the 
metabolites production in the most polar region, in particular between minute 8.5 – 9 
an overexpression of a compound that could be the responsible for the bioactivity is 
clear.  
 
 
Figure 6: Comparison of Lysobacter sp. T1 HPLC chromatograms when it is grown in co-cultivation 
(blue line) and in pure culture (black line). The two chromatograms are exactly superimposable except 
for the most polar region in which there is an enhanced production of a compound in the co-cultivation 
condition.   
 
1.4 Discussion 
 
The alarming widespread of the antimicrobial resistance problem is an effect of the 
unappropriated use of antibiotics. From the discovery of antibiotics in the 1950s the 
worldwide population was able to successfully defeat infections disease using these 
powerful molecules. Followed an era defined “Golden Age” because of the discovery 
of numerous new and effective antibiotics [13]. Mass production of that molecules 
and chemical synthesis based on natural structures guaranteed protection against 
most of the pathogen bacteria. On the other hand, the prolonged and uncontrolled 
use of antibiotics led to the rapid evolution of multidrug resistant bacteria becoming a 
serious problem [14]. There is the pressing need to discover novel bioactive 
compounds and the bioprospecting of microorganisms inhabiting extreme 
environments could be a promising strategy. In this work, the attention has been 
focused on Antarctica. This extreme continent preserves a huge biodiversity and is 
still unexplored [15]. Shallow water Antarctic sediments have been collected and 
subjected to different procedures, growing microbes in solid and in liquid for 45 days 
to allow the development of slow-growing strains [16]. By the liquid approach, a 
changing in the microbial population during the time was detected. The objective of 
this approach was to induce the competition among microorganisms leading to the 
selection of the antimicrobial producers. Most of the tested strains showed no 
bioactivity (in the selected conditions) while four of them showed a partial or total 
inhibition activity against MDR bacteria. Among 74 strains subjected to cross 
streaking assay [17] one identified as Pseudomonas gessardii C5 was selected for 
the capability to inhibit the growth of S. aureus and B. metallica. The optimization of 
this assay allowed the screening of all selected bacteria overcoming the limitation in 
the use of the same medium for tester and target strains. Liquid inhibition assay 
confirmed the antimicrobial potential of this strain against a wide panel of pathogens, 
in particular against Gram-positive bacteria. This strain is a fluorescent, Gram-
negative, rod-shaped bacterium isolated from natural mineral waters in France [18] 
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and based on 16S rRNA analysis, P. gessardii has been placed in the P. fluorescens 
group [19]. The genus Pseudomonas has a prominent role in the biotechnological 
and pharmaceutical industry for its capability to produce a wide range of bioactive 
compounds, but few studies focused the attention on P. gessardii, that is known as 
lipases producers [20] and as a naphthalene degrading strains [21]. The purification 
of the bioactive compounds produced by P. gessardii C5 led to the identification of a 
family of rhamnolipids. This class of glycolipids was discovered as a product of 
several bacterial strains, like Pseudomonas aeruginosa, Burkholderia spp. and 
others [22]. At best of our knowledge, no reports describe the purification and 
identification of rhamnolipids from P. gessardii. Although many different rhamnolipids 
have been described from Pseudomonas spp. using mass spectrometry, very often 
they are not purified and evaluated for the bioactivity. Compounds 3 and 5 identified 
from P. gessardii C5 have never been isolated so far, indicating that Pseudomonas 
strains are able to produce a wide range of this class of molecules. In agreement with 
their hydrophobic nature, these compounds eluted at a high percentage of 
acetonitrile (in a system Water/ACN, reverse phase C18-HPLC). As extensively 
reported in literature [23-25], the analysis of the negative pseudo-molecular ion [M-
H]-, obtained by ESI-HRMS gave information on the molecular formula, whereas the 
analysis of the key fragment ion arising from the cleavage of the ester linkage 
between the two β-hydroxy fatty acid units allowed to discriminate between 
congeners with asymmetric fatty acid units. In addition, the fractionation of the crude 
extract also gave an enriched fraction that contains as determined by LC-HRESIMS 
analysis, in positive mode, a mixture of 3-(3-hydroxyalkanoyloxy) alkanoic acids that 
lack the carbohydrate moiety and represent precursors of rhamnolipids. These 
compounds have been rarely isolated as components of the rhamnolipid fraction of 
bacteria [26]. As compared with other rhamnolipid-producing Pseudomonas strains, 
the observed relative composition of rhamnolipid components of the Antarctic of P. 
gessardii C5 revealed some distinctive features. Usually, monorhamnolipids 
represent a small fraction of the total amount of RL produced. Typically, P. 
aeruginosa strains produce between 75 and 80 % of di-RL and only between 20 and 
25 % of mono-RL [27] and this proportion of mono-RL/di-RL is conserved through the 
entire RL production period. Structural analyses demonstrated a molecular 
population in the studied Antarctic strain composed mainly of monorhamnolipids. 
Because of their chemical structure and composition (they have a glycosyl head 
group, a rhamnose moiety, and a 3-(hydroxyalkanoyloxy) alkanoic acid (HAA) fatty 
acid tail), rhamnolipids perform several potential functions in bacteria: as powerful 
biosurfactants are involved in the uptake and biodegradation of poorly soluble 
substrates and are essential for surface motility and biofilm development [22]. They 
have numerous industrial applications, such as in agriculture, for soil remediation 
[28], cosmetics, as active ingredient effective for several skin treatments [29] and 
detergents, used in detergent compositions, laundry products, shampoos and soaps 
[30]. Recently, they have emerged as potential antimicrobials against a broad range 
of pathogens such as Staphylococcus, Mycobacterium, and Bacillus, and significant 
activity against a number of Gram-negative species, including Serratia marcescens, 
Enterobacter aerogenes, and Klebsiella pneumoniae [31-33]. Rhamnolipids act like 
synthetic surfactants and their proposed mechanism of action consists of 
intercalation into biological membranes and destruction by their permeabilising effect 
leading to cell death [34]. This class of compounds was isolated from P. aeruginosa 
but considering the pathogenicity of this strain novel species are of biotechnological 
interest for a safer production. Moreover, the capability of P. gessardii C5 as 
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producers of rhamnolipids and lipases makes this strain an important candidate for 
the bioremediation. For this purpose, different hydrocarbons, especially oil wastes, 
will be used as substrate for bacterial growth trying to stimulate the metabolism of P. 
gessardii C5 increasing the rhamnolipids production and inducing the expression of 
different types of rhamnolipids [35]. By this approach is possible to stimulate, induce 
or optimize the production of rhamnolipids but even other compounds. As a fact, it 
has been demonstrated that varying the growth conditions (nutrients, temperature, 
pH, environment) is possible to induce the expression of silent genes. Many 
experiments applying an OSMAC (One Strain Many Compounds) led to the 
discovery of previously unknown compounds [36, 37]. Beside the OSMAC approach 
other techniques are used. During last years, the concept of axenic cultures or 
classic cultivation methods was replaced by the idea of microbial community. In 
Nature, microorganisms interact in different ways to benefit each other within a 
community. Potentially, their genome can encode for a huge amount of different and 
novel bioactive compounds, which could be exploited for pharmaceutical and 
biotechnological applications [38]. Bacterial or fungal co-cultivation is a new powerful 
emerging tool for enhancing the chemical diversity of microorganisms [39, 40] and it 
seems to be a promising strategy to induce the expression of different bioactive 
molecules. This method can be applied between bacteria-bacteria, fungi-fungi and 
bacteria-fungi. The critical point for this approach is the selection of microorganisms 
for co-cultivation. There are no defined indications or protocols for that, but 
considering that communication is one of key factors, microorganisms isolated from 
the same environment and able to grow close to each other could be considered 
promising candidates for this experiment. In this work, P. gessardii C5 was subjected 
to co-cultivation experiments together with other bacteria isolated from the same 
environment (P. fluorescens T28, Lysobacter sp. T1 and Pseudochrobactrum sp. 
T2), but no significant results were obtained. Two Antarctic strains, instead, 
Lysobacter sp. (T1) and Pseudochrobactrum sp. (T2), the only bacteria isolated after 
45 days of incubation on the same agar plates from Antarctic sediments, showed 
promising results in the co-cultivation system. In particular, Lysobacter sp. T1 
showed and increased inhibition activity, of about 15 fold, against S. aureus when it 
grows in presence of Pseudochrobactrum sp. T2 compared with the control. The 
metabolism variation corresponded to a changing in bacterial colour, resulting darker 
than the pure culture. Genome sequence analysis revealed that each Lysobacter 
species has  gene  clusters  for  the  production  of  12-16 secondary  metabolites 
showing a high chemical variability [41]. The problem is that many of these genes are 
silent. According to these preliminary results and the recent papers about Lysobacter 
sp. as an important source of new compounds, this strain will be subjected to further 
studies applying co-cultivation and OSMAC approach.  
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1.6 Supplementary materials 
 
 
Figure S1: A) HRESIMS negative Compound 1. B) HRESIMSMS negative Compound 1. 
 
 
Figure S2: A) HRESIMS negative Compound 2. B) HRESIMSMS negative Compound 2. 
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Figure S3: A) HRESIMS negative Compound 3. B) HRESIMSMS negative Compound 3. 
 
 
Figure S4: A) HRESIMS negative Compound 4. B) HRESIMSMS negative Compound 4. 
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Figure S5: HRESIMSMS negative Compound 5. 
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Table S6: NMR data of 3 and 5 in CD3OD. a 100 MHz; b 400 MHz. 
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Isolation of an Antarctic bacterium Aequorivita sp. 
by Miniaturized Culture Chip as a producer of  
novel bioactive compounds 
 
Abstract 
The access to microbial diversity is greatly hampered by standard current cultivation 
techniques. Even today, cultivation is often required to access as-yet-uncultured or 
rare microorganisms, and novel secondary metabolites from these sources may lead 
to a “Golden Age” of new drugs with tremendous benefit for human health. In this 
work, a novel approach, which mimics the natural environment by using a 
Miniaturized Culture Chip (MCC) method, allowed the isolation of several bacterial 
strains from Antarctic shallow water sediments. One of the strains, identified as 
Aequorivita sp. was a Gram-negative Antarctic bacterium belonging to the family of 
Flavobacteriaceae and resulted to be a strain unexplored for the production of 
antimicrobial compounds. The whole genome of Aequorivita sp. was sequenced and 
a genomics approach was used to identify the presence of biosynthetic gene clusters 
(BGCs). The newly isolated showed antimicrobial activity towards a panel of 
Multidrug Resistant (MDR) bacteria and antihelminthic activity towards the nematode 
Caenorhabditis elegans. The purification of active compounds revealed the 
identification of three new aminolipids showing antimicrobial activity. This is the first 
multi-approach investigation on the genomics and biotechnological potential of this 
bacterium with the findings suggesting it as a promising candidate for pharmaceutical 
applications. 
 
2.1 Introduction 
 
The number of bacterial species in the world range from 107 to 109 [1], but most have 
never been observed or cultivated. Culture-independent methods have demonstrated 
the enormous richness of biodiversity in the microbial world [2, 3]. The “challenge of 
uncultivable microorganisms” is a topic that has been concerning scientists for many 
years. It is well known as the Great Plate Count Anomaly [4, 5] based on the 
observation, that less than 1% of microbes present in an environmental sample is 
cultivable in vitro. Solutions to this problem could facilitate the discovery of new 
strains holding novel and different features which the biotechnology could exploit. 
The reasons for the unculturability are diverse and many are probably unknown. It is 
clear that certain bacteria need specific requirements for the growth, only present in 
their habitats, such as the presence of certain microbial communities or the need of 
specific physical or chemical characteristics of the natural environment (light, oxygen, 
pH, pressure, temperature etc.) [6]. Among the strategies for the isolation and 
cultivation of new or atypical microorganisms, the simulation of the natural 
environment is one of the most promising. The use of innovative devices that are 
able to mimic natural conditions enhances the chance to cultivate different microbial 
species [7-9]. The isolation of new strains is also aimed at the exploration and 
exploitation of natural products they biosynthesize, developing novel antimicrobial 
lead compounds to counteract the spread of multidrug resistant (MDR) bacteria. 
Recently, the World Health Organization 
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(http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/) 
published its first ever list of antibiotic-resistant "priority pathogens" – a catalogue of 
12 families of bacteria that pose the greatest threat to human health. The list 
includes, among the others, MDR bacteria such as Acinetobacter baumannii, 
Pseudomonas aeruginosa and methicillin resistant Staphyloccoccus aureus (MRSA). 
They can provoke recalcitrant infectious especially in hospitals where they are the 
major challenge to patient safety resulting in one of the leading cause of death in the 
US and Europe with a high cost for the public health [10]. The redundancy in the 
discovery of already known antibiotics produced by well-known species increases the 
demand of searching novel drugs. Furthermore, when looking for new antibiotics or 
new molecules of pharmaceutical interest, the screening of microorganisms from 
extreme environments may lead to the identification of novel strains that can provide 
new formerly untapped compounds for white or green biotechnology [11].  Antarctica 
is one of the most extreme places on Earth. The isolated and unique nature of 
Antarctica, characterised by low temperatures, oligotrophic environment, long periods 
of light/dark, drawing the attention of scientists. The reasons are obvious; in 
comparison to many overexplored tropical areas, Antarctica and the ocean that 
surrounds it is home of a large number of unknown organisms adapted to the 
“extremely cold temperatures and conditions”. These “extremophiles” exhibit physical 
and chemical adaptations not found elsewhere on the planet [12]. Bacteria belonging 
to the genus Aequorivita have been isolated from terrestrial and marine Antarctic 
habitats. They are members of the family Flavobacteriaceae and their 
biotechnological potential has not been investigated. Herein we report the isolation of 
Aequorivita sp. by employing the Miniaturized Culture Chip (MCC) method, the whole 
genomic sequencing of this strain, the analysis of the biosynthetic gene clusters, the 
evaluation of its antimicrobial and anthelmintic potential of intracellular extracts and 
finally the purification and identification of new antimicrobial compounds. To our 
knowledge, this is the first report aimed at the exploitation of Aequorivita genus as a 
source of bioactive compounds. 
 
2.2 Material and Methods 
 
Collection of Antarctic sediments 
Shallow water (50 cm depth) sediments were collected from 3 different sites during 
an expedition in the framework of National Antarctic Research Program (PNRA) in 
the area of Edmonson Point, Antarctica, 74° 20' (74.3333°) South, 165° 8' 
(165.1333°) East, using sterile 50 mL falcon tubes. Samples were transported using 
dry ice and stored at -80 °C until the beginning of the experiments. 
 
Design, fabrication and preparation of culture chips for the isolation of 
microorganisms 
Miniaturized culture chips (MCC) were used to screen microorganisms grown to 
microcolonies [8, 9]. MCC contained arrays of microwells with a Porous Aluminium 
Oxide (PAO) base (8×36 mm, 60 µm thick, 40% porosity, 20 to 200 µm pore 
diameter) acting as a sterile filter. MCC was fabricated by patterning the wall material 
(Ordyl 300 film, Elga, Italy) using photolithography and then applying it to 8×36 mm 
strips of PAO arrayed on a silicon wafer. Walls were patterned by photolithography of 
10 µm thick Ordyl 300 film with development according to the manufacturer’s 
protocols. The resulting perforated and processed material was heat/pressure 
applied to the PAO. Platinum (10 nm) was used to sputter coat the upper surface of 
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the MCC. Wells were 180 µm diameter, spaced 160 µm in a hexagonal patterning 
with 4500 microwells per chip. MCC were sterilized using a high intensity UV ozone 
cleaner (PSD, Novascan, USA) for 15 min. For growth under near natural conditions 
were used two different conditions. Condition A, minimal: sediment was packed into a 
Petri dish and overlaid with a thin layer of agarose 1% mixed with a filtered solution 
of 0.001% FeSO4 · 7H2O. Condition B, richer: sediment was packed into a Petri dish 
and overlaid with a thin layer of agarose 1% mixed with a filtered solution of 0.001% 
FeSO4 · 7H2O, 3% Sea Salt, 1 g/L Peptone, 0.5 g/L Yeast Extract. Sterile cultivation 
chips were placed on the solidified agarose and inoculated by spreading bacteria so 
that the probability of a single cfu/well was < 0.5. After 10 and 45 days of incubation 
at 7°C, the recovery of microcolonies from wells was carried out using a fine sterile 
toothpick using a dissection microscope to visualise the target microcolony. Finally, 
picked microcolonies were dissolved in 50 µL of sterile water. Half of it was added to 
a PCR mixture to perform the identification while the other half was stored at -80 °C 
with 20% glycerol. 
 
Molecular identification and phylogenetic analysis of isolated strains 
The freeze and thaw method was used to obtain bacterial genomic DNA, which was 
used as a template for the amplification via PCR of 16S rDNA genes. PCR was 
carried out in a total volume of 50 µL containing DreamTaq PCR Master Mix (a 
ready-to-use solution containing DreamTaq DNA Polymerase, optimized DreamTaq 
buffer, MgCl2, and dNTPs) and 1 µM of primer Eub27F (Forward, seq: 5'-
AGAGTTTGATCCTGGCTCAG-3') and Univ1492R (Reverse, seq: 5'-
GGTTACCTTGTTACGACTT-3') [13]. The reaction conditions used were: one cycle 
(93 °C for 2 min), 30 cycles (92 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min), with 
a final extension of 5 min at 72 °C. PCR products were then purified, sequenced and 
submitted to BLAST for the phylogenetic analysis.  
 
Genome sequencing and assembling of Aequorivita sp.  
The DNA of Aequorivita sp., Aequorivita lipolytica CIP 107455T, and Aequorivita 
antarctica CIP 107457T strains was obtained using the Wizard® Genomic DNA 
Purification Kit, PROMEGA. The whole genome sequencing was carried out at the 
Mutualized Microbiology Platform (P2M) of the Pasteur International Bioresources 
network (PIBnet) of the Institut Pasteur, Paris, France, using the Nextera XT DNA 
sample preparation kit (Illumina, USA) for 2x150-bp paired-end sequencing as per 
the manufacturer’s instructions. All sequenced paired-ends reads were clipped and 
trimmed with AlienTrimme [14], corrected with Musket [15], merged (if needed) with 
FLASH [16], and subjected to a digital normalisation procedure with khmer [17]. For 
each sample, remaining processed reads were assembled and scaffolded with 
SPAdes [18]. Genomes were analysed using the anti-SMASH 3.0 web server 
(http://antismash.secondarymetabolites.org) and the Biosynthetic gene clusters were 
identified. 
 
Cultivation and extract preparation 
A single colony of a bacterial isolate was used to inoculate 3 mL of liquid Marine 
Broth (MB, Difco™) medium in sterile bacteriological tubes. After 48 h of incubation 
at 20 °C at 200 rpm, the culture was used to inoculate 125 mL of MB medium in a 
500 mL flask, at an initial cell concentration of 0.01 OD600/mL. The flasks were 
incubated up to five days at 20 °C at 200 rpm. The cultures were then centrifuged at 
6000 rpm at 4 °C for 30 min. Then, the exhausted culture broth and the pellet were 
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collected and subjected to extraction with ethyl acetate separately, yielding the 
extracellular and intracellular extracts, respectively. Briefly, the exhausted culture 
broths (125 mL) were subjected to organic extraction using ethyl acetate (3x 125 mL 
ratio 1:1) in a 500 mL separatory funnel. The organic phase collected was 
evaporated to dryness using a Laborota 4000 rotary evaporator (Heidolph, 
Schwabach, Germany) affording the extracellular extract. The pellet was 
mechanically disrupted using an Ultraturrax for 5 min at 10000 rpm and then 
extracted by ethyl acetate as described for the exhausted broth, providing the 
intracellular extract. The dried extracts were weighed, dissolved in 100% DMSO at 
the final concentration of 50 mg/mL and stored at -20 °C. The same procedure was 
applied for the scale-up of the culture cultivating the bacterium in 10L of growth 
medium. 
 
Pathogen bacteria growth conditions 
The following MDR strains of human pathogens were used in this work: 
Pseudomonas aeruginosa DSM 50071, Staphylococcus aureus DSM 346, 
methicillin-resistant Staphylococcus aureus (MRSA) DSM 18827, Klebsiella 
pneumonia DSM 30104. Every strain was bought at Leibniz Institute DSMZ-German 
Collection of Microorganisms and Cell Cultures, Braunschweig, Germany. The 
strains were routinely grown at 37°C in Luria Bertani medium (10 g/L Tryptone, 5 g/L 
Yeast extract, 10 g/L NaCl) at 200 rpm. 
 
Antimicrobial activity  
In order to evaluate the antimicrobial potential of the Aequorivita sp. strain extracts, 
samples were placed into each well of a 96-well microtiter plate at an initial 
concentration of 2% (v/v) and serially diluted using LB medium. A single colony of 
selected pathogen strains, P. aeruginosa DSM 50071, S. aureus DSM 346, MRSA 
DSM 18827 and K. pneumoniae DSM 30104 was used to inoculate 3 mL of liquid LB 
medium in sterile bacteriological tubes. After 6–8 h of incubation, growth was 
measured by monitoring the absorbance at 600 nm and about 40,000 CFU were 
dispensed in each well of the prepared plate. Plates were incubated at 37 °C for 24 h 
and growth was measured with a Cytation3 Plate Reader (Biotek, Winoosky, VT, 
USA) by monitoring the absorbance at 600 nm. 
 
Antihelminthic activity 
In order to test the effect of crude extracts on Caenorhabtidis elegans Wild-type (WT) 
Bristol N2 obtained from the Caenorhabditis Genetic Centre (CGC) a liquid toxicity 
assay has been set-up. The assay has been performed in 24-well plates. Each well 
contained a 400 μL solution of M9 buffer, 5 μg/mL cholesterol, and Escherichia coli 
OP50 as a food source [19],  because these worms feed on bacteria, at the 
concentration of 0.5 OD/mL as nutrient source. The intracellular and extracellular 
extracts of Aequorivita sp. were then added at different concentrations to each well. 
C. elegans was synchronized by bleaching treatment [20], and 30-40 L4 worms were 
transferred to each well and incubated at 20 °C up to seven days. The wells were 
scored for living worms every 24 h. A worm was considered dead when it no longer 
responded to touch. For statistical purposes, 3 replicates per trial were carried out 
with a unique egg preparation. 1% DMSO was used as negative control.  
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Cell viability assay (MTS assay) 
The assay to determine cell survival was conducted by using HFFF2 (ECACC 
86031405) cells as target and the MTS as tetrazolium compound to determine the 
number of viable cells. Cells were seeded at 7.5 x 103 cells/well in a sterile 96-well 
microtiter plate and allowed to adhere overnight by growing at 37 °C and 5% CO2. 
The various concentrations of Aequorivita sp. intracellular extracts (30, 62, 125, 250, 
500 µg/mL) were added. DMSO, the solvent used to dissolve the extracts served as 
negative control. Three replicate wells were used per concentration. The treated cells 
were then incubated for 24 h at 37 °C and 5% CO2. After incubation, the medium was 
removed and a mixture consisting of 100 µl of fresh medium and 20 µl of reagent 
(MTS:PMS 19:1) was added to each well. The plate was again incubated for 1 h at 
37 °C and 5% CO2 in the dark to allow the reduction of MTS into a coloured formazan 
product by living cells.  In order to quantify the amount of formazan produced, directly 
proportional to the number of living cells after extracts treatment, absorbance was 
measured at 490 nm, using an ELISA plate reader. 
 
Identification of the antimicrobial compounds 
Isolated molecules were chemically characterized by NMR spectroscopy and 
HRESIMS analysis in collaboration with the GEOMAR-Biotech of Kiel (Germany). 
 
2.3 Results 
 
Isolation of Antarctic microorganisms using MCC 
An innovative device, the Miniaturized Culture Chip (MCC), was used to isolate 
Antarctic bacteria from shallow water sediments. Two different conditions, one 
minimal, containing the Antarctic sediments as only nutrient source and the other 
richer, composed by sediments, Peptone, Yeast extract and Sea Salt were tested, as 
described in MM. The MCC180.10 culture chip was directly placed on mixture 
agarose-sediments (Supplementary materials Fig. S1) and inoculated with serial 
dilutions of the same sediments present into the plates. After 10 days at 7 °C, the first 
colonies appeared, but the chip was kept in incubation up to 45 days, allowing the 
formation of slow-growing strains (Fig. 1). The minimal condition showed the same 
number of colonies (9 colonies) compared with rich medium condition (10 colonies) 
highlighting the importance of the sediments into the growth medium. A total of 19 
colonies were visualized by microscope and collected. This system simulates the 
natural habitat, in which microorganisms live in communities, and allows the 
communication among the microorganisms present on the top and under the surface 
of the chip. Another advantage of the MCC is the possibility to grow microorganisms 
using as substrate their own natural environment that could contain all the nutrients 
necessary for the growth and also avoid slow-growing strains being overgrown by 
fast-growing strains. 
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Figure 1: MCC180.10 culture chip picture. (A). Microscope view of the MCC180.10 (B). Bacterial 
colonies visible on the chip after 7 days of incubation (10X) (C). Example of GFP-transformed 
Escherichia coli grown on the chip (D). The scale bar indicates 4 mm when applied to (A) 200 µm 
when applied to (B) and 360 µm when applied to (C) and (D). 
 
Identification of bacterial isolates 
19 microorganisms were isolated from the chip and used for the phylogenetic 
analysis. The phylogenetic affiliation of bacterial isolates was performed through the 
16S rRNA genes amplification and analysis. For this purpose, the 16S rRNA genes 
were PCR amplified and the nucleotide sequence of the amplicons determined. Each 
sequence was used as a query in a BLAST search to retrieve the most similar ones. 
MEGA7 software [21] was used to align the sequences and to construct the 
phylogenetic tree shown in Figure 2. The molecular analysis showed a prevalence of 
Pseudomonas sp. and Shewanella sp. strains. Other strains such as Psychrobacter 
sp., one Algoriphagus sp. and one Aequorivita sp. were identified. This last strain, 
named, showing 96% of identity with Aequorivita sublithincola, was selected for 
further experiments because of the lack of previous studies on antimicrobial and 
antihelminthic activities.  
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Figure 2: Evolutionary relationships of taxa and showing the placement of Aequorivita sp. strain. The 
evolutionary history was inferred using the Neighbor-Joining method. The optimal tree with the sum of 
branch length = 0.58717318 is shown. The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (1000 replicates) are shown next to the branches. The tree is 
drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to 
infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite 
Likelihood method and are in the units of the number of base substitutions per site. The analysis 
involved 19 nucleotide sequences.  
 
Genome mining for Aequorivita sp. 
The newly isolated strain Aequorivita sp. was deposited in the Collection of Institut 
Pasteur (CIP), France, under accession number CIP 111184T. Due to the lack of 
information about the Aequorivita genus, the whole genomes of Aequorivita sp., A. 
lipolytica CIP 107455T and A. antarctica CIP 107457T strains were sequenced and 
subjected to a genome mining approach in order to identify the presence of 
biosynthetic gene clusters (BGCs). The antibiotics and Secondary Metabolite 
Analysis Shell (anti-SMASH) has served as a comprehensive web server and a 
stand-alone tool for the automatic genomic identification and analysis of BGCs, 
facilitating rapid genome mining of a wide range of bacterial and fungal strains. Using 
the anti-SMASH 3.0 web server is possible to compare identified BGCs with those 
encoding the biosynthetic pathways for known compounds from the “Minimum 
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Information about a Biosynthetic Gene cluster” (MIBiG) community project 
http://mibig.secondarymetabolites.org/ [22]. The gene cluster identification algorithms 
in tools such as anti-SMASH is based on the detection of one or more conserved 
protein domains using curated models; certain protein domains or domain 
combinations are indicative of biochemical functions that are specific to certain 
biosynthetic pathways; hence they can be used as “signatures” to identify certain 
classes of BGCs (Tracanna et al, 2017). The cluster arylpolyene-resorcinol, similar to 
the flexirubin biosynthetic gene cluster and the aryl polyenes (APE) biosynthetic gene 
cluster, were found in the genome of Aequorivita sp. as well as in the genome of the 
A. antarctica CIP 107457T and A. lipolytica CIP 107455T (Table 1). Different 
saccharide clusters were detected in all Aequorivita strains, mainly a cluster similar to 
the capsular polysaccharide biosynthetic gene. Furthermore, in the genome of 
Aequorivita sp. strain a gene with 69% of identity with the Type III polyketide 
synthase of Zobellia galactanivorans was detected in the gene cluster T3pks-
arylpolyene (data not shown). An NRP/Polyketide cluster was detected in the A. 
lipolytica CIP 107455T strain (Table 1). 
 
Gene Cluster Type MIBiG        BGC-ID Most similar known cluster 
Aequorivita 
sp. 
Aequorivita 
antarctica            
CIP 107457T 
Aequorivita 
lipolytica              
CIP 107455T 
Cf_saccharide Saccharide BGC0000733_c1 
Capsular polysaccharide biosynthetic 
gene cluster 
X X X 
Cf_saccharide Saccharide BGC0000773_c1  
Lipopolysaccharide biosynthetic gene 
cluster;  O-antigen biosynthetic gene 
cluster 
X - - 
Arylpolyene-
Resorcinol 
Polyketide BGC0000838_c1  
Flexirubin biosynthetic gene cluster;  Aryl 
polyene (APE) biosynthetic gene cluster  
X X X 
Cf_saccharide Saccharide BGC0000766_c1 
Exopolysaccharide biosynthetic gene 
cluster 
- X X 
Cf_saccharide Saccharide BGC0000781_c1 O-antigen biosynthetic gene cluster X - - 
Cf_saccharide Saccharide BGC0000791_c1 
O-antigen biosynthetic gene cluster;  
Lipopolysaccharide biosynthetic gene 
cluster;  Exopolysaccharide biosynthetic 
gene cluster 
X - - 
Cf_saccharide Saccharide BGC0000799_c1 Colanic acid biosynthetic gene cluster - X - 
Cf_saccharide 
NRP / 
Polyketide 
BGC0000960_c1 Azinomycin B biosynthetic gene cluster - - X 
Table 1: Biosynthetic gene clusters (BGCs) in the Aequorivita sp. whole genome compared with two 
Aequorivita type strains: A. antarctica CIP 107457T and A. lypolitica CIP 107455T using the anti-
SMASH 3.0 web server (http://antismash.secondarymetabolites.org). 
 
Evaluation of the antimicrobial activity of Aequorivita sp. 
In order to evaluate the capability of the new isolate to produce antimicrobial 
compounds, intracellular and extracellular extracts from an Aequorivita sp. culture 
were generated. The bacterium was grown for five days in MB, producing a very 
strong yellow pigment, as described in MM. The IC50 (half maximal inhibitory 
concentration) of the intracellular and extracellular extracts was calculated towards a 
panel of MDR pathogenic bacteria composed by P. aeruginosa, methicillin-resistant 
S. aureus (MRSA), K. pneumoniae and A. baumannii. Results summarised in Table 
2 show the absence of growth inhibition of the extracellular extract, while the 
intracellular extract shows an antimicrobial effect against three out four-target 
pathogens with a promising activity against MRSA, IC50 value of 120 µg/mL (this 
concentration is referred to the crude extract).  
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 IC50 value 
Strain Intracellular  Extracellular  
P. aeruginosa 500 µg/mL No inhibition 
MRSA 120 µg/mL No inhibition 
A. baumannii 250 µg/mL No inhibition 
K. pneumoniae No inhibition No inhibition 
Table 2: Antimicrobial activity of Aequorivita sp. intracellular and extracellular extracts against a panel 
of MDR bacteria. Bacterial growth was measured in OD600/mL. Values are reported in IC50. 
 
Antihelminthic activity of Aequorivita sp. crude extracts 
Encouraged by the antimicrobial potential showed by Aequorivita sp. towards the 
human pathogens, both intra and extracellular crude extracts were also tested for 
their ability to kill nematodes using C. elegans as a model system. Again, results 
demonstrated that the intracellular extract has significant in vitro antihelminthic effect 
after 3 days of incubation. As showed in Figure 3, it was able to kill C. elegans 
starting from a concentration of 500 µg/mL, where less than 20% of worms survived, 
until 120 µg/mL that correspond to the IC50 value where the percentage of survival 
was about 50% suggesting a dose-response effect.  
 
 
 
Figure 3: Antihelminthic activity of Aequorivita sp. extracellular and intracellular extracts vs C. 
elegans. Activity is expressed as the percentage of surviving worms after 3 days of incubation in the 
presence of extracts. Worms grew on OP50 cells and 1% DMSO are used as control. 
 
Bioassay-guided purification of Aequorivita sp. intracellular extract 
Aequorivita sp. strain was grown in 10L MB medium for 5 days at 20°C, then the 
culture was centrifuged and the exhausted broth was filtered and stored at 4 °C for 
further analysis, while the intracellular material was extracted by ultraturrax and ethyl 
acetate. Subsequently, the crude extract (1 g) was fractionated with a SPE C18 
Cartridge. Elution was performed stepwise with an increasing methanol 
concentration. The 4 eluted fractions were collected, dried and dissolved in DMSO to 
perform bioassay at a stock concentration of 50 mg/mL. The fraction eluted at 100% 
methanol was shown to be the most active one exhibiting, an increased antimicrobial 
activity against MRSA with a IC50 of 15 µg/mL (Table 3), almost tenfold compared 
with crude extract and anthelmintic activity against C. elegans (Data not shown).  
 
 
Strain IC50 value of 100% MeOH fraction 
P. aeruginosa 120 µg/mL 
MRSA 15 µg/mL 
A. baumannii 120 µg/mL 
K. pneumoniae 500 µg/mL 
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Table 3: Antimicrobial activity of the fraction eluted at 100% methanol against a panel of MDR 
bacteria. Bacterial growth was measured in OD600/mL. Values are reported in IC50. 
 
For this reason, the 100% methanol fraction (120mg) obtained from SPE purification 
was purified by semiprep RP-HPLC/ELSD affording 21 peaks which were dried and 
dissolved in DMSO to perform the activity assays. Data obtained revealed the 
inhibitory activity against MRSA of eight compounds (Table 4) 
 
  IC50 value of isolated compounds 
Strain C-1 C-2 C-3 C-4 C-5 C-6 C-7 C-8 
MRSA 
>200 
µg/mL 
>200 
µg/mL 
>200 
µg/mL 
90 
µg/mL 
22  
µg/mL 
145 
µg/mL 
>200 
µg/mL 
58  
µg/mL 
Table 4: Antimicrobial activity of pure compounds against MRSA. Values are reported in IC50 
 
Identification of antimicrobial compounds 
The analyses based on the 1H-NMR and HRMS spectra of active peaks allowed 
identifying the chemical family of the compounds. They are aminolipids, N-(β-
acyloxyacil)-amino acids including glycine and serine residue, saturated and 
unsaturated lipidic chains with different numbers of carbons (Fig. 4). The calculation 
of molecular formula and the comparison of the NMR data with the literature afforded 
the structure identification. The elucidated compounds are: compound 1, N- 15-
Methyl-3-(13-methyl-tetradecanoyloxy)-hexadecanoylglycine, compound 2, N- 15-
Methyl-3-(13-methyl-tetradecanoyloxy)-hexadecanoylglycine methylester, 
compound 3, N- 15-Methyl-3-(13-methyl-4Z-tetradecanoyloxy)-
hexadecanoylglycine, compound 4, N- 15-Methyl-3-(13-methyl-4Z-
tetradecanoyloxy)-hexadecanoylglycine methylester, compound 5, N- 15-Methyl-3-
(12-methyl-tridecanoyloxy)-hexadecanoylglycine, compound 6, WB-3559 A, 
compound 7, WB-3559 B, both isolated by Uchida et. al. from Flavobacterium sp. 
[23] and compound 8, methylester of WB-35559B. Dereplication of isolated 
compounds, based on 1D, 2D NMR and HRMS indicated that compounds 2, 4 and 
8 are new aminolipids. (The structure elucidation of the compounds was performed in 
collaboration with GEOMAR-Biotech of Kiel, Germany). 
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Figure 4: Molecular structures of antimicrobial compounds isolated from Aequorivita sp. 
 
Preliminary toxicity evaluation of 100% MeOH fraction  
The active 100% methanol fraction containing the mixture of aminolipids was 
assayed towards human cells to check the toxicity (In this case the fraction was used 
instead of the purified compounds for a preliminary toxicity evaluation. Further 
studies will allow the characterization of compounds). Cell viability assay was carried 
out by using human fibroblastic cells HFFF2 (ECACC 86031405), that represent a 
model system of skin cells. The value of the percentage of viable cells after the 
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treatment was obtained by normalising the value of absorbance in each well with the 
correspondent value of absorbance of DMSO, at the same concentration. Results 
demonstrated that the 100% MeOH fraction has no toxic effect against HFFF2 cells 
at concentration tested for the antimicrobial and anthelmintic activity (Fig. 5). Results 
are shown as percentage of viable cells after the treatment at different sample 
concentration.  
 
 
Figure 5: Cell viability assay using HFFF2 cells in the presence of different concentration of 100% 
MeOH fraction of Aequorivita sp. Values are reported as percentage of surviving cells. 
 
Preliminary analysis for the sustainable production of bioactive compounds 
exploiting Aequorivita sp. wastes 
In order to make competitive the aminolipids production, a preliminary system for the 
valorisation of wastes was set-up. For each gram of intracellular extract from 
Aequorivita sp. many litres of MB are wasted. To overcome this problem, the 
exhausted broth generated from the bacterial cultivation was filtered using a 0.22 µm 
stericup (autoclaving the liquid broth is energy consuming and furthermore could 
denaturate many substances present in the medium) and used as a liquid substrate 
for other microorganisms. For this “second cultivation step” microorganisms isolated 
from the same sediments of Aequorivita sp. were used, such as Pseudomonas sp. 
11L, Psychrobacter sp. 1M, Shewanella sp. 1L and Algoriphagus sp. 14L. First, the 
capability of the selected microorganisms to grow in an “exhausted broth” was 
checked evaluating the turbidity of the medium. As a fact, after only 24 h all the 
selected bacteria were grown (Fig. 6) suggesting that in the medium are still present 
nutrients or molecules produced during the “first cultivation step”.  
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Figure 6: In the figure is schematized the process of exhausted broth recycling of Aequorivita sp. The 
first step is the separation of the pellet from the supernatant. Then, while the pellet is used for the 
production of antimicrobial compounds, the supernatant is filtered (0,22 µm filter) and used as liquid 
substrate for other strains. 
 
After five days of incubation, the selected bacteria were analysed for their 
antimicrobial potential extracting the supernatant of the new cultivations by ethyl 
acetate and performing a liquid inhibition assay against MDR bacteria. Results 
revealed that crude extracts obtained by Pseudomonas sp. 11L and Algoriphagus sp. 
14L inhibited S. aureus and B. metallica respectively (Table 5-6). Further studies are 
needed for the optimisation of this method. 
 
Extract                 
concentration 
1
mg/mL 
0,5 
mg/mL 
0,25 
mg/mL 
0,13 
mg/mL 
0,06 
mg/mL 
0,03 
mg/mL 
0,015 
mg/mL 
0,007 
mg/mL 
0,003 
mg/mL 
DMSO + 
Cells 
Cells    
only 
Pseudomonas sp. 11L 100 100 90 80 50 0 0 0 0 0 0 
Psychrobacter sp. 1M 0 0 0 0 0 0 0 0 0 0 0 
Shewanella sp. 1L 0 0 0 0 0 0 0 0 0 0 0 
Algoriphagus sp. 14L 0 0 0 0 0 0 0 0 0 0 0 
Table 5: Antimicrobial activity of crude extracts obtained from four strains grown in Aequorivita sp. 
exhausted broth against S. aureus. Bacterial growth is measured in OD600/mL. Red colour indicates 
the strong inhibition of the extract at a certain concentration while green colour indicates no inhibition.  
 
 
Extract                 
concentration 
1
mg/mL 
0,5 
mg/mL 
0,25 
mg/mL 
0,13 
mg/mL 
0,06 
mg/mL 
0,03 
mg/mL 
0,015 
mg/mL 
0,007 
mg/mL 
0,003 
mg/mL 
DMSO + 
Cells 
Cells   
only 
Pseudomonas sp. 11L 40 15 0 0 0 0 0 0 0 0 0 
Psychrobacter sp. 1M 0 0 0 0 0 0 0 0 0 0 0 
Shewanella sp. 1L 20 0 0 0 0 0 0 0 0 0 0 
Algoriphagus sp. 14L 100 96 75 53 20 0 0 0 0 0 0 
Table 6: Antimicrobial activity of crude extracts obtained from four strains grown in Aequorivita sp. 
exhausted broth against B. metallica. Bacterial growth is measured in OD600/mL. Red colour indicates 
the strong inhibition of the extract at a certain concentration while green colour indicates no inhibition. 
 
 
2.4 Discussion 
 
The lack of new antibiotic molecules entering the market and the overuse/misuse of 
the existing antibiotics are generating an alarming situation for human health. The 
spread of MDR bacteria underlines the urgent search for new antimicrobial lead 
compounds. Microbes have been a major source of natural antibiotics and playing a 
very significant role in historical and modern antibiotic drug discovery. However, 
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these efforts are seriously hampered by the culturability of microbes in artificial 
laboratory conditions. Furthermore, genetic (or genomic) studies show that the 
majority of the BGCs remain silent due to lack of natural cues, ecological challenges 
in such standard growth conditions and need to be induced using alternative 
methods [24]. Hence different strategies are mandatory for successful cultivation and 
the isolation of underexplored strains from new, untapped environments. In this work, 
we have isolated microorganisms from an extreme environment, Antarctica, using a 
Miniaturized Culture Chip (MCC). Antarctica is one of the most hostile places on 
Earth, and a survey conducted by the international Census of Marine Life 
demonstrated the extraordinary biodiversity of this extreme habitat and the marine 
environment around it [25]. This habitat has incredibly low temperatures and other 
extreme traits, such as long light/dark period and low availability of nutrients. These 
extreme conditions would be expected to shape the evolution and adaptation of both 
primary and secondary metabolism of the Antarctic bacteria, to lead to the production 
of unprecedented chemical molecules with unique functions [26]. In this research, the 
application of the MCC to Antarctic sediments led to the isolation of different genera 
of bacteria. This method allowed the isolation of microorganisms growing them 
directly on environmental sediments. The main idea of MCC is the simulation of the 
natural environment, laying the chip directly on natural sediments that become the 
only substrate for the growth of microorganisms. The same idea is the base of iCHIP, 
a new system composed of microwells and semipermeable membranes, which 
allowed the isolation of a new β-proteobacteria provisionally named Eleftheria terrae 
able to produce a new antibiotic, the teixobactin [27]. By the diffusion of nutrients 
obtained from sediments and by stimuli received from the bacterial community 
present in it, microbes can grow on the top of the chip as microcolonies. They are 
partially protected by the overgrowth of neighbouring microbes but available for 
imaging and recovery. One strain in particular, identified as Aequorivita sp. and 
deposited in the Collection of Institut Pasteur, France, attracted the attention for the 
almost complete absence of previous works especially about the production of 
bioactive compounds. Few strains belonging to the genus Aequorivita have been 
isolated from Antarctica (sea water, ice, algae, stones) [28] and even fewer studies 
about these bacteria were performed. The lack of previous works addressed to 
evaluate the bioactive potential of this genus makes this strain a good candidate for 
further analysis. One strain of this genus was isolated from the chip, together with an 
Algoriphagus sp. and other bacteria belonging to the genus Pseudomonas sp., 
Shewanella sp. and Psychrobacter sp. For this experiment, two nutritional conditions 
(A and B) were applied. In the condition A (minimal medium) sediments were 
covered by a thin layer of agarose mixed with FeSO4. This element was proved to be 
a key factor for the isolation of previously uncultivated bacteria [29]. The condition B 
(rich medium) had the same composition of condition A but supplemented with sea 
salt, peptone and yeast extract. This differentiation was made to see some changes 
in the microbial community, but surprisingly, a similar number of colonies were 
observed without any significant variation in the strains distribution, with only 
exception of Aequorivita sp. and Algoriphagus sp. which were retrieved exclusively 
from condition A. This could indicate that bacteria used natural sediments as primary 
nutrient source for the growth, highlighting the importance of the reproduced 
microenvironment for bacterial survival. The diffusion of nutrients from sediments, the 
communication among microorganisms up and down the MCC, the protection of 
slower growing strains by an overgrowth of more aggressive strains by the MCC 
wells could be all important factors that allowed the cultivation of microorganisms. 
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The whole genome sequencing of Aequorivita sp. and its analysis by anti-SMASH 
indicated the presence of several BGCs. BGCs have been described for hundreds of 
bacterial metabolites and even though they can be accurately identified and 
quantified, the question still remains, which of these are most likely to encode the 
production of potent antimicrobials. The most prominent family of BGCs already 
described includes two subfamilies distributed throughout the Proteobacteria; their 
products are aryl polyenes (APEs) [30] also found in Aequorivita sp. and in other 
strains. Although these clusters are widely divergent in sequence, their small 
molecules are remarkably conserved, suggesting the important role that these 
compounds play in Gram-negative cell biology. The APEs are structurally similar to 
flexirubin, a pigment that was previously isolated from Flexibacter elegans. A role for 
APEs in protecting Gram-negative bacteria against oxidative stress make them 
analogous to the chemically similar Gram-positive carotenoids [30] although 
biosynthetically distinct. The strong yellow/orange Aequorivita sp. pigmentation could 
support the production of these pigments, and antioxidant assays are needed to 
confirm the expression of these genes. Numerous gene clusters encoding genes for 
saccharides were found. Cell-associated saccharides such as lipopolysaccharides, 
capsular polysaccharides and polysaccharides are known to play key roles in 
microbe-host and microbe-microbe interactions, while diffusible saccharides have a 
range of biological activities, most notably antibacterial [31, 32]. Non-ribosomal 
peptides (NRPs) are the major multi-modular enzyme complex which synthesizes 
secondary metabolites in bacteria and fungi and some genes were found in A. 
lypolitica CIP 107455T, while in the genome of Aequorivita sp. a gene with 69% of 
identity with the Type III polyketide synthase of Zobellia galactanivorans was 
detected in the gene cluster T3pks-arylpolyene (data not shown), indicating a 
possible role of this cluster in the production of polyketides. The analysis of the 
antimicrobial potential of this bacterium revealed a promising inhibitory activity 
against some MDR pathogenic bacteria. In particular, the intracellular crude extract 
of Aequorivita sp. (obtained by mechanical disruption of bacterial cells followed by 
organic extraction) showed promising antimicrobial effect against MRSA which is the 
causative agents of serious hospital infections representing today one of the most 
dangerous antibiotic-resistant bacteria. vancomycin and linezolid have become the 
only drugs to counteract the infection but, treatment failures, adverse side effects and 
the early developed resistance make necessary alternative therapies [33]. Even if 
most of the antimicrobials are expressed outside the cell, the intracellular nature of 
some antimicrobial compounds is not unusual, although their ecological role is still 
not clear [34, 35]. They could be involved in intracellular signalling or have a 
defensive role [36]. Moreover, we have shown Aequorivita sp. intracellular extract to 
be active towards the nematode C. elegans used as model system for studies of 
anthelmintic drugs which are urgently needed to treat and control diseases which 
affect millions of people each year [37]. A preliminary purification step allowed the 
isolation of a fraction with an increased bioactivity against the MDR bacteria, 
especially MRSA without toxic effects against human cell lines. The final purification 
and identification of pure molecules revealed the presence of 8 active aminolipids, 5 
known compounds and 3 never isolated before. Some bacteria species are known to 
contain in their inner and outer membranes amphipathic lipids based on one or two 
amino acids linked to a fatty acid through an amide bond and sometimes another 
through an ester bond. New forms of these compounds are frequently described in 
marine organisms. Among them, unusual structures formed of fatty acids and amino 
acid derivatives (bromotyrosine) were isolated from sponges, they were named 
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mololipids and showed anti-HIV activity [38]. Numerous examples of bacterial lipids 
containing amino acids or peptides are known [39] and many of them display 
interesting properties as antibiotics [40] and biosurfactants [41] attracting the interest 
of pharmaceutical and biotechnological industries. Compound 1 produced by 
Aequorivita sp. was previously isolated from a marine bacterium Cytophaga sp. 
SANK 71996 as N-type calcium channel blockers [42]. Cytophaga strains are Gram-
negative, rod-shaped or filamentous gliding bacteria. Some of these bacteria belong 
to 'Cytophaga-Flavobacterium-Bacteroides' group. The genus Aequorivita, belongs to 
the family Flavobacteriaceae and contains five recognized species: Aequorivita 
antarctica, A. lipolytica, A. crocea, A. sublithincola [28] isolated from Antarctic 
terrestrial and marine habitats and A. capsosiphonis [43] isolated from a green alga 
collected from the South Sea, Republic of Korea. Previous analysis of fatty acids 
revealed the presence of aminolipids but they were never isolated, characterized or 
used as antimicrobial molecules. To our knowledge, this is the first report describing 
the potential of Aequorivita spp. as producers of antimicrobial compounds. The multi-
approach applied in this work involving the isolation by MCC, the analysis of BGCs 
and the final identification of new antimicrobial compounds emphasize the 
importance of unexplored microorganisms as a source of new bioactive compounds 
for biotechnological and pharmaceutical applications. 
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2.6 Supplementary materials 
 
 
Figure S1. Miniaturized Culture Chip (MCC) is basically, a large number of miniaturized “Petri Dishes 
on-a-chip” made out of porous aluminium oxide (PAO). The sediments in the Petri dish are covered 
with a thin layer of agarose. The chip is placed directly on the agarose layer and then is inoculated 
with a solution obtained from the same sediments. Nutrients from beneath the chip diffuse through the 
pores to the surface and consequently supply microorganisms with nutrients that are growing on top of 
the surface as microcolonies. 
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Abstract 
 
Marine fungi represent an important but still largely unexplored source of novel and 
potentially bioactive secondary metabolites. The antimicrobial activity of nine sterile 
mycelia isolated from the green alga Flabellia petiolata collected from the 
Mediterranean Sea was tested on four antibiotic-resistant bacterial strains using 
extracellular and intracellular extracts obtained from each fungal strain. The isolated 
fungi were identified at the molecular level and assigned to one of the 
Dothideomycetes, Sordariomycetes or Eurotiomycetes classes. Following 
assessment of inhibition of bacterial growth (IC50), all crude extracts were subjected 
to preliminary 1H NMR and TLC analysis. According to preliminary pharmacologic 
and spectroscopic/chromatographic results, extracts of fungal strains MUT 4865, 
classified as Beauveria bassiana, and MUT 4861, classified as Microascacea sp.2, 
were selected for LC-HRMS analysis. Chemical profiling of antibacterial extracts from 
MUT 4861 and MUT 4865 by LC-HRMS allowed identification of the main 
components of the crude extracts. Several sphingosine bases were identified, 
including a compound previously unreported from natural sources, which gave a 
rationale to the broad spectrum of antibacterial activity exhibited. 
 
3.1 Introduction 
 
The worldwide diffusion of antibiotic-resistant microorganisms requires the 
development of new efficient antimicrobial molecules. For more than half a century, 
the main strategy for obtaining new antimicrobial agents has consisted of 
semisynthetic remodelling of natural products. However, drugs obtained in this way 
are only temporarily effective against pathogenic microorganisms, which develop 
antibiotic resistance [1]. The problem regarding microbial resistance to antibiotics 
may be overcome by the discovery of new natural products which, due to their 
chemical novelty, could inhibit unknown single or multiple microbial targets. The 
search for natural products of pharmaceutical interest in the marine environment has 
been progressing at an unprecedented rate, resulting in the discovery of a number of 
molecules, many of which have new carbon skeletons and interesting biological 
activities [2,3]. Among marine microorganisms, fungi play a crucial role, as they are a 
reservoir of biologically active secondary metabolites [4-6]. Recently, several new 
metabolites from marine fungi have been reported to display notable antibacterial 
activities [7-9]. Despite their proven biosynthetic potential, scientific research has not 
intensively focused on marine fungi for seeking new drugs [10]. However, promising 
fungi are equipped with gene clusters potentially involved in the biosynthesis of 
secondary metabolites [11]. Therefore, research into the isolation, identification and 
characterization of new fungal strains capable of producing useful bioactive natural 
72 
 
compounds should be carried out. Hence, the aim of this work was to assess the 
antibacterial potential of nine sterile mycelia isolated from the green alga Flabellia 
petiolata collected from the Mediterranean Sea, against some representative 
multidrug-resistant (MDR) bacteria, relevant in cystic fibrosis and nosocomial 
infections, and to analyse the chemical profiles of the most active fungal crude 
extracts. 
 
3.2 Material and methods 
 
Fungal strains 
Fungi were isolated and roughly identified from the green alga F. petiolata collected 
in March 2010 near Elba Island in the Mediterranean Sea [12], and are preserved at 
the Mycotheca Universitatis Taurinensis - MUT (DBIOS - University of Turin). All 
selected fungi were revealed to be sterile mycelia and were identified by molecular 
analysis (Table 1). 
 
MUT code Fungal taxa GenBank accession 
  
number ITS and 
LSU 
   
4883 Biatriospora sp. KR014352 
  KP671728 
4865 Beauveria bassiana KR014380 
  KP671729 
4860 Massarina sp. KR014362 
  KP671730 
4885 Microascacea sp.1 KR014356 
  KP671717 
4861 Microascacea sp.2 KR014360 
  KP671746 
4859 Roussoellacea sp.1 KR014355 
  KP671716 
4886 Roussoellacea sp.2 KR014358 
  KP671720 
4966 Roussoellacea sp.3 KR014366 
  KP671740 
4979 Knufia petricola KR014376 
   
Table 1: MUT code, taxonomic assessment of sterile mycelia isolated from F. petiolata and GenBank accession 
numbers. 
 
Molecular, bioinformatics and phylogenetic analyses 
Genomic DNA was extracted using cetyl trimethyl ammonium bromide (CTAB, 
Sigma-Aldrich St. Louis, USA) according to the protocol of Graham et al. [13]. The 
nrDNA internal transcribed spacer (ITS) and large ribosomal subunit (LSU) partial 
regions were amplified using universal primers ITS1F/ITS4 (Sigma-Aldrich St. Louis, 
USA) and LR0R/LR7, as previously described [14]. Amplification products were 
sequenced at Macrogen Europe (The Netherlands). Sequences were checked and 
assembled using Sequencher 4.9 software and compared to those available in the 
GenBank database using the BLASTn option of the BLAST program 
(www.blast.ncbi.nlm.nih.gov) and CBS Mycobank pairwise sequence alignment 
(www.mycobank.org). Newly generated sequences were deposited in the GenBank 
database and were assigned accession numbers reported in Table 1. Phylogenetic 
analysis was performed only on LSU sequences, as comparable ITS sequences of 
fungi studied in this article are rarely found in public databases and/or are poorly 
informative. LSU sequences were selected for phylogenetic analysis on the basis of 
BLASTn and CBS results. Two sequence datasets were composed, following 
reference [14] for Pleosporales and reference [15] for Sordariomycetes. Alignments 
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were generated using MEGA 5.10 [16] and manually refined. Phylogenetic analyses 
were performed using both Bayesian inference (BI; MrBayse3.2.2) [17] and 
maximum likelihood (ML; RAxML v.7.3.2) [18] approaches, as previously described 
[14]. Bayesian posterior probability (BPP) values over 0.6 (with MLB over 50%) are 
reported in the resulting trees. 
 
Fungal growth conditions 
Preliminary growth condition tests were performed in order to define the most 
effective and appropriate medium for inducing production of bioactive secondary 
metabolites in the selected fungal strains. Each fungal strain was inoculated in 
duplicate by 10 agar plugs of 5 mm diameter cut from the edge of actively growing 
culture onto malt extract agar in 150 mL flasks containing 100 mL of three different 
media: PCB (10 g of crushed potatoes and 10 g of crushed carrots in 1 L of ddH2O), 
MeCl (20 g malt extract, 17 g NaCl in 1 L of ddH2O) and WST30 (10 g glucose 
monohydrate, 5 g soya peptone, 3 g 
malt extract, 3 g yeast extract, 30 g NaCl). Flasks were incubated in the dark at 24 °C 
and rotated at 150 rpm. The broth and mycelium of each strain were collected after 2 
and 4 weeks and submitted to an extraction procedure for preliminary biochemical 
analysis (see below). MeCl medium and 4-week incubation were selected as the best 
conditions (24 °C in the dark). Hence, each fungus was inoculated (100 agar plugs of 
5 mm diameter) in 2 L flasks containing 1.5 L of MeCl, which was incubated in the 
dark at 24 °C at 180 rpm for 4 weeks. 
 
Extract preparation 
Samples were centrifuged at 11,200 x rcf for 30 min at 4 °C and filtrated in order to 
separate mycelium from culture broth. Supernatants were extracted with ethyl 
acetate (EtOAc) and the resulting extracts were dried out using a Rotavapor, 
weighed, solubilized in dimethyl sulfoxide (DMSO, 100%) at a final concentration of 
100 mg/mL and stored at -20 °C. The presence of antimicrobial compounds in the 
mycelia was also evaluated. In order to efficiently lyse the cells, different mechanical 
disruption methods were used in a sequential manner. The first step consisted of 
homogenization with Ultra Turrax T25 (IKA-Werke, Staufen, Germany). The 
homogenate was then washed twice with 20 mL of EtOAc to recover intracellular 
extract; in addition, to improve fungal lysis, mycelia were treated with liquid nitrogen 
(15 mL N2/g mycelium). Samples were transferred to precooled mortar and minced 
under liquid nitrogen with a pestle and washed twice with 20 mL of EtOAc. At the last 
step, to completely destroy the membrane, all mycelium was transferred and 
processed in a Potter-Elvehjem homogenizer (Sigma-Aldrich, Saint Louis, MO) in the 
presence of EtOAc. Subsequently, the powdered mycelium was transferred to a 
separator funnel and mixed five times with two volumes of EtOAc. In order to 
increase the yield of some extracts, mycelia were further soaked in acetone for 18 h 
under agitation. The whole EtOAc and acetone fractions were collected and dried out 
using a Rotavapor. Final extracts were weighed, solubilized in DMSO (100%) at a 
final concentration of 100 mg/mL and stored at -20 °C. 
 
Antimicrobial assay 
The extracts produced as such were checked for the ability to inhibit growth of a 
selected panel of human pathogens. An IC50 assay was used to evaluate the 
concentration of extracts at which bacterial target growth was inhibited by 50%. The 
following multidrug-resistant bacteria were used for antimicrobial screening: 
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Burkholderia metallica LMG 24068 [19], Pseudomonas aeruginosa PA01 [20], 
Klebsiella pneumoniae DF12SA [21] and Staphylococcus aureus 6538P [22]. All 
bacteria were routinely grown at 37 °C in lysogeny broth (5 g yeast extract, 10 g 
sodium chloride, 10 g tryptone in 1 L of ddH2O), with the exception of S. aureus, 
which was grown in Mueller Hinton broth (Applichem, Darmstadt, Germany). Extracts 
were placed into each well of a 96-well microtiter plate at an initial concentration of 2 
mg/mL and serially 2-fold-diluted using the appropriate medium. Wells containing 
only DMSO (2% v/v) were used as a control to determine the effect of this solvent on 
bacterial growth. Cells were prepared as follows: a single colony of each pathogenic 
strain was used to inoculate 3 mL of liquid medium in a sterile bacteriological tube. 
After 5-8 h of incubation, growth was measured by monitoring the absorbance at 600 
nm and about 40,000 colony-forming units were dispensed into each well of the 
prepared plate. Plates were incubated at 37 °C for 20 h and growth was measured 
using a VICTOR X Multilabel Plate Reader (PerkinElmer, Waltham, MA) by 
monitoring the absorbance at 600 nm. 
 
Metabolic profiling of crude extracts 
All crude extracts were subjected to thin layer chromatography (TLC) analysis and 1H 
nuclear magnetic resonance (NMR). TLC analysis was carried out on Alugram silica 
gel G/UV254 plates with a solvent mixture of different polarity using vanillin reagent 
as the revelation system; 1H NMR analysis were performed with a Varian INOVA 400 
MHz instrument in CDCl3 solvent at room temperature with tetramethylsilane (TMS) 
as internal reference. Selected extracts were analyzed using an LTQ XL liquid 
chromatography high resolution mass spectrometry system (LC-HRMS) 
(ThermoScientific) equipped with an Accelera 600 pump and Accelera auto sampler 
system. A volume of 10 µL of sample was injected at a concentration of 10 mg/mL in 
methanol. The mixture was separated on a Phenomenex LUNA C8 (150 x 2.1 mm, 5 
mm particle size) column at a flow rate of 200 mL/min using an acetonitrile-water 
gradient. Mobile phase A was 90% H2O 10% acetonitrile (ACN) 0.1% formic acid 
(FA) and mobile phase B was 10% H2O 90% ACN 0.1% FA; the gradient started at 
10% B up to 90% B in 70 min and was kept at 90% of B for 10 min before the 
reequilibration step. The mass spectrometer operated in positive electrospray 
ionization (ESI) mode at 4 kV capillary voltage and 280 °C. The calibration procedure 
was carried out using a ThermoScientific positive calibration solution composed of 
caffeine, MRFA and Ultramark. All spectra were acquired in the m/z range from 280 
to 700 u.m.a., setting resolution at 30,000; MSMS spectra were acquired in an 
opportune m/z range using 35 collision energy. Thermo-Scientific software Xcalibur 
was used to obtain molecular formulas (MFs). MFs deduced by high-resolution 
electrospray ionization mass spectrometry (HRESIMS) were checked by available 
data banks [23-25] and, in the case of alternative structures, they were discriminated 
by MSn analysis using data available in the literature [26] or ex novo analysis, and 
then by checking diagnostic signals in the 1H NMR spectrum of the crude extracts. 
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3.3 Results 
 
Phylogeny and taxonomic identification of fungal isolates 
Molecular and phylogenetic analyses revealed that strains MUT 4859, MUT 4860, 
MUT 4883, MUT 4886 and MUT 4966 belong to the order Pleosporales 
(Dothideomycetes class). In particular, MUT 4860 was identified as Massarina sp. 
and MUT 4883 as Biatriospora sp., both clustering in the Biatriosporaceae family, 
while MUT 4859, MUT 4886 and MUT 4966 were identified at the family level 
(Roussoellaceae) [27]. MUT 4861, MUT 4865, and MUT 4885 belonged to the 
Sordariomycetes class; specifically, MUT 4865 belonged to Beauveria bassiana, 
while MUT 4861 and MUT 4885 clustered within the Microascaceae family. Finally, 
MUT 4979 was identified as Knufia petricola (syn. Sarcinomyces petricola, Incertae 
sedis, Chaetothyriales, Eurotiomycetes) by both ITS and LSU sequences (homology 
percentage = 99%). 
 
Antimicrobial activity 
In order to select the best growth medium for producing the antimicrobial 
compounds, preliminary extractions and antimicrobial assays were performed on 
small-scale cultures of fungi grown in MeCl, PCB and WST30. These analyses 
demonstrated that fungi grown in MeCl exhibited the highest degree of antimicrobial 
activity (Supplementary materials Table S1). This medium was therefore selected for 
further experiments. Moreover, the antimicrobial potentials of the extracellular and 
intracellular extracts were compared; results revealed that the latter exhibited the 
highest yield and activity (Supplementary materials Table S2). Starting from these 
preliminary results, extracts obtained from mycelium lysates were used for 
antimicrobial screening, targeting a panel of MDR human pathogens. The 
antimicrobial activity displayed by the different fungal strains against the four MDR 
bacteria is reported in Table 2 as IC50 values. The resistance of each strain to 
ampicillin, chloramphenicol, kanamycin, tetracycline and trimethoprim was confirmed 
by liquid inhibition assays. Extracts produced from strains MUT 4861, MUT 4865 and 
MUT 4979 were shown to be the most active and promising ones. In particular, MUT 
4861 was able to strongly inhibit B. metallica (IC50 0.5-0.25 mg/mL) and S. aureus, 
and was the only one to show, by both EtOAc and acetone extracts, an inhibitory 
effect against P. aeruginosa. Both extracts from MUT 4865 were able to inhibit B. 
metallica and S. aureus (IC50 0.5-0.25), and the EtOAc extracts also showed 
inhibition against K. pneumoniae. No effects were observed against P. aeruginosa. 
The extract from MUT 4979 showed antimicrobial activity against three out of the four 
pathogens (IC50 1.0-0.25), with the exception of K. pneumoniae. Extracts of MUT 
4859, 4860, and 4966 only showed significant activity against B. metallica and S. 
aureus, which were the bacterial strains most sensitive to the fungal extracts. MUT 
4883, 4885 and 4886 extracts were the weakest strains, showing no significant 
effects against the target bacteria. Acetone extracts showed similar antimicrobial 
activity compared to EtOAc extracts. The only exception was MUT 4861, of which the 
acetone extract was more active than the EtOAc extract. Overall, the most promising 
strains were MUT 4865, 4979 and 4861, which exhibited the highest degree of 
antibacterial activity. 
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 Fungi IC50 (mg/mL) 
 MUT code 
B. metallica 
LMG 24068  
P. aeruginosa 
PA01   
 K. pneumoniae 
DF12SA  
S. aureus 
6538P  
              
  Ethyl acetate Acetone Ethyl acetate Acetone Ethyl acetate Acetone Ethyl acetate Acetone 
              
 4859 0.5-0.25 >2.0 >2.0 >2.0  >2.0 >2.0  1.0-0.5 >2.0 
 4860 0.5-0.25 0.5-0.25 >2.0 >2.0  >2.0 >2.0  2.0-1.0 >2.0 
 4861 0.5-0.25 0.5-0.25  2.0-1.0 1.0-0.5 >2.0 2.0-1.0  1.0-0.5 ND 
 4865 0.5-0.25 0.5-0.25 >2.0 >2.0   1.0-0.5 >2.0  0.5-0.25 0.5-0.25 
 4979 1.0-0.5 ND  1.0-0.5 ND >2.0 ND  0.5-0.25 ND 
 4966 1.0-0.5 ND >2.0 ND >2.0 ND  1.0-0.5 ND 
 4885 2.0-1.0 ND >2.0 ND >2.0 ND  2.0-1.0 ND 
 4886 2.0-1.0 ND >2.0 ND >2.0 ND  2.0-1.0 ND 
 4883 2.0-1.0 ND  2.0-1.0 ND >2.0 ND  2.0-1.0 ND 
Table 2: Antimicrobial activity of the fungal intracellular extracts vs four bacterial strains belonging to 
different species. The data are reported as capacity to inhibit the microorganism growth in more than 
50% (IC50). Growth in the presence of 2% DMSO was considered as 100% growth. ND: Not detected. 
 
Secondary metabolite analyses 
Based on results of preliminary pharmacologic, spectroscopic and chromatographic 
screening, extracts of MUT 4865 and MUT 4861 were selected for chemical profiling 
and were analysed by LC-HRMS. Other strains did not produce detectable amounts 
of secondary metabolites under culture conditions; therefore, their potential for 
secondary metabolite production will require further investigation. 
 
Beauveria bassiana MUT 4865 
Both acetone and EtOAc extracts were subjected to HRESIMS analysis (Fig. 1A). 
Compound 1 was analysed for C22H43O2N by HRMS analysis (calculated for 
C22H43NO2 Na:376.3192, found [M+Na]+: 376.3195). In the MS2 spectrum, the 
sequential loss of one ammonia and two neutral water molecules indicated the 
presence of one amino and two hydroxyl groups. The planar structure of this 
compound was deduced from analysis of the MS3 spectrum, which showed a 
fragmentation pattern compatible with localization of the two double bonds at the 
unusual positions of 6 and 17, revealing that it corresponded to the long chain 
sphingadienine (Fig. 2). Therefore, a 1,3-dihydroxy-2-amino-6,17-docosadiene 
structure was tentatively proposed. Assignment of the relative configuration of the 
two contiguous stereogenic centers as well as of the two double bonds would require 
isolation of the compound from a large-scale cultivation batch of the fungal strain 
(see Fig. 3). As shown in Fig. 1B, the acetone extract did not contain a detectable 
amount of compound 1, whereas some sphingosine compounds were detected, such 
as phytosphingosine (2), dihydrosphingosine (3) and phytoceramide C2 (4). 
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Fig. 1. ESI positive mode base peak chromatograms of the active samples MUT 4865 EtOAc extract 
(panel A), acetone extract (panel B) and MUT 4861 acetone extract (panel C). Numbers above the 
peaks identify the metabolites listed in Tables 2 and 3. 
 
 
Fig. 2. MS3 ESI positive mode spectrum of the precursor ion at m/z 359.30 derived from MSMS at m/z 
376.31 and its proposed fragmentation. 
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MS2 pattern analysis (Table 3) led to a straightforward assignment of a planar 
structure for these compounds. Compound 5, which was present in both EtOAc and 
acetone extracts, was tentatively identified as aphidicolin; compound 6 was 
tentatively identified as fusoxysporone and compound 7, a minor component of the 
EtOAc extract, was identified as bis (2-ethylhexyl) hexanedioic acid. 
 
Strain RT 
(min)  
MS and MS/MS Suggested 
MF 
Proposed structure 
 
 
 
 
 
 
 
 
 
 
 
MUT4865 
23.20 376.3195 [M+Na]+ (ppm: 
1.049) 
MS2 (S5): 359.29, 341.28; 
MS3 see Figure 2 
C22H43 NO2 1,3-dihydroxy-2-amino-
6,17-docosadiene (1) 
 
28.32 318.30015 (ppm: -0.379) 
MS2 (S5) :300.29, 282.29, 
265.33  
C18H39 NO3 2-aminooctadecan-1,3,4-
triol 
(4-hydroxysphiganine or 
phytosphingosine) (2) 
29.11 302.30543 (ppm: 0.245) 
MS2 (S6): 284.29, 266.31, 
249.26 
C18H39NO2 1,3-dihydroxy-2-
aminooctadecane  
(dihydrosphingosine) (3) 
30.03 360.31079 (ppm: -0,126) 
MS2 (S6) :342.31,324.32, 
300.31, 264.30, 212.19 
C20H42NO4 N- Acetyl-1,3,4-
trihydroxy-2-
aminooctadecane 
(phytoceramide C2) (4) 
45.65 339.25320 (ppm: - 0.876) C20H34O4 Aphidicolin (5) 
54.04 287.23634 (ppm: 0.584) 
MS2 (S7): 269.23, 203.14, 
175.11 [25] 
C20H30O Fusoxysporone (6) 
60.38 395.3309 (ppm: 0.145) C28H42O Ergosta-5,7,22-trien-3--
ol (ergosterol)  
62.89 393.3153 (ppm: 0.401) C28H40O Ergosta-4,6,8(14),22-
tetraen-3-one  
66.49 371.31453 (ppm: -1.056)  
MS2 (S7): 259.01, 240.70, 
146.9, 128.9, 110.99 [36] 
C22H42O4 Bis(2-ethylhexyl) 
hexanedioic acid (7) 
Table 3: Annotated peaks observed in the chromatograms of the EtOAc and Acetone extracts of 
Beauveria bassiana MUT 4865. 
 
 
 
 
 
 
 
79 
 
Microascacea sp.2 MUT 4861 
The EtOAc extract contained a very complex mixture of lipid and polysaccharide 
components evidenced by 1H NMR analysis which, however, did not allow its de-
replication by HRESIMS. Conversely, the main components of the acetone extract 
were identified. For this fungal strain, two polar components were revealed to be 
sphingoid bases. In addition to phytosphingosine (2), an “unusual” sphingoid base 
with a molecular formula C19H39NO3 was detected. The MS2 spectrum showed 
fragmentation peaks resulting in sequential loss of three water molecules, whereas 
no ammonia elimination was measured. This finding could suggest involvement of a 
nitrogen atom in an azetidine ring, as in isomeric penaresidins A and B. Although the 
fragmentation pattern observed in the MS3 spectrum is compatible with these 
structures, no ambiguous information relative to the position of the hydroxyl groups, 
methyl branching, or even the nature of unsaturation could be obtained. Finally, 
Scopularide A (8) [28] was identified by MF analysis and by diagnostic MS2 
fragmentations (Fig. 3, Table 4). 
 
 
 
 
Fig. 3. Chemical structures of secondary metabolites (1e8) identified by LC-HRMS in bioactive 
extracts of B. bassiana MUT 4865 and MUT 4861. 
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Strain RT 
(min)  
MS and MSn Suggested 
MF 
Proposed structure 
MUT  
 
 
 
 
 
 
 
 
 
 
4861 
31.52 318.30002 (ppm -0.756) 
MS2 (S5): 300.29, 282.29, 
265.33  
C18H39 NO3 2-amino-octadecane- 
1,3,4 triol (4-
hydroxysphiganine or 
phytosphingosine) (2) 
34.29 330.30024 (ppm -0.031) 
MS2 (S8): 312.26, 294.33, 
282.32, 256.32 
MS3[@ 294.33)] (S9): 
266.33, 168.18, 154.07, 
140.11, 133.01, 126.0, 
111.96, 97.94) 
C19H39NO3  
49.05 672.43291 (ppm-0.166) 
MS2 (S8) 654.5, 525.3, 
507.2, 454.2, 436.2, 323.1 
[38] 
C36H57N5O7 Scopularide A (8)  
58.14 409.3101 (ppm 0) C28H40O2 ergostane 
59.94 393.3154 (ppm 0) C28H40O ergostane 
65.6 395.3307 (ppm 0) 
 
C28H42O ergosterol 
73.06 371.31576 (ppm 0) 
MS2 (S7): 259.01, 240.70, 
146.9, 128.9, 110.99 
 
C22H42O4 Bis(2-ethylhexyl) 
hexanedioic acid (7) 
77.20 377.32019 (ppm 0) C28H40 Ergosta-3,5,7,9(11),22-
pentaene 
Table 4: Annotated peaks observed in the chromatograms of the acetone extract of Microascacea 
sp.2 MUT 4861. 
 
3.4 Discussion 
 
In this study, the green marine alga F. petiolata was chosen as a source of promising 
marine fungi, since it had been previously demonstrated that fungi isolated from 
marine algae showed strong antimicrobial activity against several human pathogenic 
bacteria [29], probably deriving from the ability to protect their algal host from 
external threats [30]. Identifying new fungal strains could lead to the discovery of new 
and unusual compounds with biotechnological and pharmaceutical applications. The 
first step of this work was the phylogenetic affiliation of fungal strains, which was 
carried out according to molecular and phylogenetic analysis. Massarina sp. (MUT 
4860) and Biatriospora sp. (MUT 4883) clustered in the Biatriosporaceae family, 
which accommodates genera that have often been collected from a range of both 
terrestrial and aquatic hosts, and are commonly found in decaying submerged 
intertidal mangrove wood [27]. Recently, it has been demonstrated that a strain 
identified as Biatriospora sp. is an efficient producer of secondary metabolites, in 
particular, naphthoquinone derivatives [31]. MUT 4859, MUT 4886 and MUT 4966 
clustered in the Roussoellaceae family, which includes species of saprobic fungi 
isolated from decaying bamboo culms or palm fronds [32]. B. bassiana (MUT 4865) 
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is a marine isolate of well-known enthomopathogenic fungus, commonly isolated 
from decaying arthropods or from plant tissue as an endophyte [33]. On the basis of 
molecular and phylogenetic data, MUT 4861 and MUT 4885 could be considered 
putative new species and even new genera of the Microascales, a small order of 
primarily saprobic fungi in soil, rotting vegetation and dung. Some species of this 
order are responsible for plant diseases, while other members cause human 
diseases [34]. K. petricola (MUT 4979) is an algicolous strain of microcolonial fungus 
with a meristematic-black yeast morphology that has only been previously found on 
stone substrates, such as unlichenized fungus with its natural ecological niche [35]. 
To the best of our knowledge, this is the first report of the presence of this species in 
a marine environment. As the antimicrobial activity of these algicolous fungi on MDR 
bacteria (according to the results of the bioassay tests) was in agreement with the 
known antimicrobial potential of marine fungi, further investigations are 
recommended, also taking into account the value of producing antimicrobial 
compounds from new taxonomic entities that have never been previously explored. 
The most promising fungal strains were MUT 4865, 4979 and 4861, which exhibited 
the highest degree of antibacterial activity. MUT 4865, identified as B. bassiana, 
representatives of which are well known producers of insecticides and antimicrobials 
[36], showed strong activity against all pathogens tested. For K. petricola (MUT 
4979), this is the first report of antimicrobial activity exhibited by fungal extracts from 
this species. Further studies are necessary, considering that the class this organism 
belongs to (Eurotiomycetes) includes several species (e.g. Aspergillus spp., 
Paecilomyces spp., Penicillium spp.) that have been reported to be a source of many 
antimicrobial metabolites [37,38]. Finally, MUT 4861 is of special interest due to the 
fact that it is presumed to belong to a new species of Microascaceae, a family that 
includes a number of fungi capable of producing several antimicrobial secondary 
metabolites [37,38]. Chemical profiling of the most active crude extracts highlighted 
the presence of chemically diverse metabolites. In particular, both strains were found 
to contain sphingoid bases. Diverse variants of the long-chain bases sphingosine and 
phytosphingosine have been reported from marine organisms, especially sponges 
and tunicates [39,40], but to the best of our knowledge, this is the first report of 
sphingosine-free bases from marine fungi. In particular, long-chain sphingadienine 2-
aminodocosa- 6,17-dien-1,3-diol has never been described as a free base or as a 
component of polar lipids from natural sources. Related docosa-4,15-sphingadienine 
and 4-hydroxy-docosa-15-sphingenine have been reported as components in 
sphingophosphonolipids from the marine gastropod Turbo cornutus [41]. It is 
noteworthy that recent years have witnessed an everincreasing interest in the so-
called “sphingoid bases” for their role in regulation of physiological and pathological 
conditions [42]. In particular, a recent study [43] revealed that sphingoid long-chain 
bases displayed antibacterial activity against a broad spectrum of pathogenic 
bacteria, including P. aeruginosa, Acinetobacter baumannii, Haemophilus influenzae, 
Moraxella catarrhalis and even Burkholderia cepacia, at nanomolar to low micromolar 
concentrations. Therefore, although we cannot exclude a priori the possibility that the 
antimicrobial activity could rely on a combination of different molecules, compound 1 
and co-occurring sphingosines 2, 3 and 4, previously reported to be common 
components of fungal membrane sphingolipids [44], may be responsible for the 
antimicrobial effects exhibited by MUT 4865 crude extracts towards the pathogenic 
bacteria investigated thus far. However, tests with the purified compound will be 
necessary to validate this hypothesis. Regarding the other tentatively identified 
components of MUT 4865 extracts, aphidicolin is a tetracyclic diterpene with known 
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antiviral and antimitotic properties, first isolated from the fungus Cephalosporium 
aphidicola [45]. Fusoxysporone, is a viscidane-type diterpene first isolated from 
Fusarium oxysporum [46], and is also found as a component of the cytotoxic extracts 
of a Penicillium strain isolated from bivalve mollusks [47]. To the best of our 
knowledge, no biological activities have thus far been described for this compound. 
Compound 7, identified as bis (2-ethylhexyl) hexanedioic acid, is known as a 
plasticizer [48], and is described as a component of cyanobacteria, Antarctic [49] and 
terrestrial [50] strains of Streptomyces, and of a tropical plant [51]. Sphingosine-
related compounds were also detected in the EtOAc extract of Microascacea sp.2 
MUT 4861, which also contains a member of the class of so-called anhydrophyto 
sphingosines; in particular, the detected compound is isomeric with azetidine-derived 
penaresidins A and B, which were first isolated from the marine sponge Penares sp. 
[52]. Conversely, compound 8 is a cyclodepsipeptide scopularide A, a molecule with 
antiproliferative activity previously isolated from a marine strain of the fungus 
Scopulariopsis brevicaulis [28], belonging to the same Microascaceae family 
assigned to MUT 4861. In conclusion, nine selected strains isolated from the green 
alga F. petiolata were chosen as a promising source of antimicrobial compounds. All 
fungal strains demonstrated interesting antimicrobial activity against four human 
pathogenic MDR bacteria. Crude extracts of three of the selected fungal strains, 
preserved at the MUT collection as MUT 4865, MUT 4979 and MUT 4861, were able 
to strongly inhibit the entire panel of pathogens. Chemical profiling of the antibacterial 
extracts from B. bassiana, MUT 4865 and Microascacea sp.2, MUT 4861, by LC-
HRMS allowed identification of the main components of the crude extracts. No 
detectable amounts of peptide mycotoxins, such as beauvericin or enniatins, known 
for their antimicrobial and anti-tumor activities [53], were detected. Isolation of 
several sphingosine bases, including compound 1, previously unreported from 
natural sources, gave a rationale to the broad spectrum of antibacterial activity 
exhibited by the crude extract of this fungal strain. Further experiments aimed at 
isolation of pure compounds and determination of their biological activity are currently 
under way. 
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3.6 Supplementary materials 
 
 
 
MUT Code 
Growth media 
MeCl WST30 PCB 
4859 55 ± 2.4 38 ± 1.2 ND 
4860 50 ± 1.7 48 ± 2.4 ND 
4861 65 ± 3.5 38 ± 4.5 10 ± 0.6 
4865 60 ±1.0 60 ± 5.7 ND 
4883 25 ± 0.7 ND 20 ± 1.2 
4885 35 ± 1.4 33 ±3.2 25 ± 0.3 
4886 30 ± 0.4 40 ± 4.3 40 ± 0.9 
4966 50 ± 0.8 10 ± 0.2 ND 
4979 62 ± 1.4 45 ± 3.5 38 ± 0.9 
 
Table S1. Selection of the best fungi growth media antimicrobial compounds production.  The 
table reports the antimicrobial activity as the percentage of inhibition of a selected target bacterium 
(Burkholderia metallica LMG 24068) in presence of the fungal extracellular extracts from the three 
different growth media. MeCl medium showed the best antimicrobial activity. ND: Not detected. 
 
 
 
 
MUT Code 
 
Intracellular extract 
 
Extracellular extract 
4859 70 ± 3.4 40 ± 3.2 
4860 67 ± 2.1 33 ±1.3  
4861 56 ± 0.9 30 ± 0.5 
4865 60 ± 2.5 32 ± 0.7 
4883 54 ± 3.1 25 ± 0.8 
4885 76 ± 4.3 33 ± 1.2 
4886 60 ± 3.8 10 ± 0.6 
4966 60 ± 2.1 15 ± 1.3 
4979 60 ± 6.5 30 ± 2.1 
 
Table S2. Comparison of the antimicrobial activity between intracellular and extracellular. 
extracts. Antimicrobial activity is reported as the percentage of inhibition of the selected target 
bacterium (Burkholderia metallica LMG 24068) in presence of intracellular and extracellular fungal 
extracts. Intracellular extracts resulted to be the most active. 
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Conclusions 
 
The discovery of bioactive marine natural products at the end of the last decades 
increased the interest in marine bioprospecting, which has today evolved towards a 
more biotechnological prospection exploiting marine microorganisms as a source of 
new products. In this work, the bioprospecting of extreme marine environment 
allowed the isolation and identification of different species of bacteria and fungi which 
have been exploited for the production of antimicrobial compounds. The application 
and optimization of a “Drug discovery” pipeline allowed the selection of promising 
strains able to inhibit the growth of a panel of MDR bacteria. Novel isolation and 
cultivation methods were applied discovering new antimicrobial molecules 
highlighting the importance to shift from classic microbiological techniques to more 
innovative ones. The need to overcome the problem represented by the decreasing 
of new effective antibiotics led to the exploration of different strategies. The obtained 
results showed a very promising antimicrobial effect of new molecules structurally 
related to fatty acids. Over last years, these class of compounds attracted the 
attention of scientists because of their multiple applications. As antibiotics, they can 
elude the resistance mechanisms interacting directly with the bacterial membrane. 
Moreover, they can be used in the bioremediation as biosurfactants. These 
characteristics make them interesting from a commercial point of view and future 
experiments will allow increasing the yield of the bioactive molecules to make the 
process competitive. All this work was highly focused on culture-dependent methods 
as a strategy for obtaining novel molecules, but the future of the drug discovery 
needs a synergistically approach. Culture-independent approaches are necessary to 
guide the isolation of novel promising strains. In particular, thanks to the enormous 
progress made by the omic techniques (metagenomics, metatranscriptomics and 
metabolomics) the selection of the “best” strains will be performed following the 
presence of new/unknown biosynthetic gene clusters in the microbial genome and 
evaluating their expression by metatranscriptomics and metabolomics. In addition, a 
different strategy is represented by the application of the synthetic biology through 
which organisms with new desirable biosynthetic capabilities will be built. The fighting 
against infectious bacteria is not over, but biotechnology could help to counteract this 
threat.  
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